Heteroaromatic ring sulfonamide structure compound, and pharmaceutical composition and application thereof

Abstract

The invention discloses a compound with a heteroaromatic ring sulfonamide structure as well as a pharmaceutical composition and application thereof. The invention provides a compound with a heteroaromatic ring sulfonamide structure as shown in a formula I, and pharmaceutically acceptable salts, stereoisomers, tautomers or isotope compounds thereof. The compound with the heteroaromatic ring sulfonamide structure is expected to be used for treating and / or preventing various diseases related to poly adenosine diphosphate ribose hydrolase (PARG). # imgabs0 #

Description

Technical Field

[0001] The present invention relates to a heteroaromatic ring sulfonamide structure compound, a pharmaceutical composition and application thereof. Background Art

[0002] The division and proliferation of cancer cells are often uncontrolled, resulting in a higher incidence of DNA damage and DNA repair defects, and they are more dependent on DNA damage repair mechanisms than normal cells.

[0003] Poly(ADP-ribose) polymerase (PARP), poly(ADP-ribose) hydrolase (PARG) and some other proteins play an important role in DNA repair and have become important targets for the development of anticancer drugs. PARP can bind to the DNA single-strand break site and promote the generation of poly(ADP-ribose) (PAR) chains, thereby initiating the repair process. The role of PARG is to degrade PAR on PARP and promote the completion of the entire repair cycle. Whether it is the inhibition of PARP or PARG, it will affect the entire repair process.

[0004] At present, the research and development of PARP inhibitors has achieved great success, and many drugs have been approved for marketing, which also proves the feasibility of using DNA repair proteins as targets. At the same time, PARP inhibitors also have problems such as not being effective for all patients and drug resistance. The research on PARG inhibitors is still in the exploratory stage, and there is a lot of room for research in this target direction, which is expected to fill unmet clinical needs. Summary of the invention

[0005] The technical problem to be solved by the present invention is that there is a lack of effective drugs in the prior art as PARG inhibitors for clinical treatment. To this end, the present invention provides a heteroaromatic sulfonamide structure compound, a pharmaceutical composition and application thereof. The heteroaromatic sulfonamide structure compound is expected to be used to treat and / or prevent various diseases related to PARG.

[0006] The present invention solves the above technical problems through the following technical solutions.

[0007] The present invention provides a heteroaromatic ring sulfonamide structure compound as shown in Formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or an isotope compound thereof:

[0008]

[0009] represents a single bond or a double bond;

[0010] A 3 is C or N;

[0011] A 4 N or CR4 ;

[0012] A 5 NR 5 or CR 5 ;

[0013]

[0014] R a1 is cyano or C 1-6 alkyl;

[0015] Ring Y is "a 4-12-membered heterocycloalkyl group containing 1 to 3 heteroatoms independently selected from O, S and N" or "a 4-8-membered heterocycloalkenyl group containing 1 to 3 heteroatoms independently selected from O, S and N";

[0016] R 1 for

[0017] R 11 , R 12 , R 13 , R 14 , R 15 and R 16 Independently for C 1-6 Alkyl, with one or more R 1-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl, with one or more R 1-2 Substituted C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 1-3 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, one or more R 1-4 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 1-5 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 1-6 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 1-7 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N";

[0018] R1-1 , R 1-2 , R 1-3 , R 1-4 , R 1-5 , R 1-6 and R 1-7 For halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 1a 、-NR 1b1 R 1b2 、-C(=O)OR 1c 、-C(=O)NR 1d1 R 1d2 、-S(O) 2 NR 1e1 R 1e2 、-S(O) 2 R 1f , C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, or "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; when there are multiple substituents, they may be the same or different;

[0019] R 1a , R 1b1 , R 1b2 , R 1c , R 1d1 , R 1d2 , R 1e1 , R 1e2 and R 1f are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0020] n is 0, 1, 2, 3, 4, 5 or 6;

[0021] R 2 For halogen, hydroxyl, cyano, oxo, C 1-6 Alkyl, with one or more R 2-1 Substituted C 1-6 Alkyl, C 3-8 Cycloalkyl, with one or more R 2-2 Substituted C 3-8 Cycloalkyl, C 2-6Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 2a 、-NR 2b1 R 2b2 、-C(=O)OR 2c or -C(=O)NR 2d1 R 2d2 ; or, when n is 2, 3, 4, 5 or 6, any two R 2 connected to each other, independently together with the atoms in the ring to which they are connected, form a 3-8 membered carbocyclic ring, or a 3-8 membered heterocyclic ring containing 1-3 heteroatoms, which are independently selected from O, S and N;

[0022] R 2-1 and R 2-2 are independently halogen, cyano, C 1-6 Alkyl-O-, hydroxyl, -C(=O)R 22a 、-NR 22b1 R 22b2 、-C(=O)OR 22c or -C(=O)NR 22d1 R 22d2 ;

[0023] R 2a , R 2b1 , R 2b2 , R 2c , R 2d1 , R 2d2 , R 22a , R 22b1 , R 22b2 , R 22c , R 22d1 and R 22d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0024] R 3 is a 5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N, or is replaced by one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N";

[0025] R 3-1 For halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C substituted by one or more halogens 1-6 Alkyl, with one or more -OC 1-6 Alkyl substituted C 1-6 Alkyl, -OC1-6 Alkyl, -SC 1-6 Alkyl, -OC substituted by one or more halogens 1-6 Alkyl, pentafluorinated sulfur, or -SC substituted by one or more halogens 1-6 Alkyl; when there are multiple substituents, they may be the same or different;

[0026] R 4 For hydrogen, halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0027] R 5 For hydrogen, C 1-6 Alkyl, or one or more R 5-1 Substituted C 1-6 alkyl;

[0028] R 5-1 For deuterium, halogen, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, Hydroxyl, -OC 1-6 Alkyl, -C(=O)R 5a 、-NR 5b1 R 5b2 、-C(=O)OR 5c 、-C(=O)NR 5d1 R 5d2 , C 6-20 Aryl, one or more R 5-1-1 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 5-1-2 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 3-12 Cycloalkyl, with one or more R 5-1-3 Substituted C 3-12 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 5-1-4 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 5-1-5 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 5-1-6 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms, which are independently selected from O, S and N"; when there are multiple substituents, they may be the same or different;

[0029] R 5-1-1 , R 5-1-2 , R 5-1-3 , R 5-1-4 , R 5-1-5 and R 5-1-6 are independently halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0030] R 5a , R 5b1 , R 5b2 , R 5c , R 5d1 and R 5d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0031] The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds:

[0032] N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide,

[0033] N-(1-cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-1-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide.

[0034] In one embodiment, the structure of the heteroaromatic sulfonamide compound shown in Formula I is shown in Formula II:

[0035]

[0036] in, represents a single bond or a double bond;

[0037] A 1 is C, CH or N;

[0038] A 3 is C or N;

[0039] A 4 N or CR 4 ;

[0040] A 5 NR 5 or CR 5 ;

[0041]

[0042] R a1 is cyano or C 1-6 alkyl;

[0043] R 1 for

[0044] R 11 , R 12 , R 13 , R 14 , R 15 and R 16 Independently for C 1-6 Alkyl, with one or more R 1-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl, with one or more R 1-2 Substituted C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 1-3 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, one or more R 1-4 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 1-5 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 1-6 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 1-7 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N";

[0045] R 1-1 , R 1-2 , R 1-3 , R 1-4 , R 1-5 , R 1-6 and R 1-7 For halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 1a、-NR 1b1 R 1b2 、-C(=O)OR 1c 、-C(=O)NR 1d1 R 1d2 、-S(O) 2 NR 1e1 R 1e2 、-S(O) 2 R 1f , C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, or "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; when there are multiple substituents, they may be the same or different;

[0046] R 1a , R 1b1 , R 1b2 , R 1c , R 1d1 , R 1d2 , R 1e1 , R 1e2 and R 1f are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0047] n is 0, 1, 2, 3, 4, 5 or 6;

[0048] R 2 For halogen, hydroxyl, cyano, oxo, C 1-6 Alkyl, with one or more R 2-1 Substituted C 1-6 Alkyl, C 3-8 Cycloalkyl, with one or more R 2-2 Substituted C 3-8 Cycloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 2a 、-NR 2b1 R 2b2 、-C(=O)OR 2c or -C(=O)NR 2d1 R 2d2 ; or, when n is 2, 3, 4, 5 or 6, any two R 2connected to each other, independently together with the atoms in the ring to which they are connected, form a 3-8 membered carbocyclic ring or a 3-8 membered heterocyclic ring containing 1-3 heteroatoms, which are independently selected from O, S and N;

[0049] R 2-1 and R 2-2 are independently halogen, cyano, C 1-6 Alkyl-O-, hydroxyl, -C(=O)R 22a 、-NR 22b1 R 22b2 、-C(=O)OR 22c or -C(=O)NR 22d1 R 22d2 ;

[0050] R 2a , R 2b1 , R 2b2 , R 2c , R 2d1 , R 2d2 , R 22a , R 22b1 , R 22b2 , R 22c , R 22d1 and R 22d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0051] R 3 is a 5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N, or is replaced by one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N";

[0052] R 3-1 For halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C substituted by one or more halogens 1-6 Alkyl, with one or more -OC 1-6 Alkyl substituted C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC substituted by one or more halogens 1-6 Alkyl, pentafluorinated sulfur, or -SC substituted by one or more halogens 1-6 Alkyl; when there are multiple substituents, they may be the same or different;

[0053] R 4 For hydrogen, halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0054] R 5 For hydrogen, C 1-6 Alkyl, or one or more R 5-1 Substituted C 1-6 alkyl;

[0055] R 5-1 For deuterium, halogen, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, Hydroxyl, -OC 1-6 Alkyl, -C(=O)R 5a 、-NR 5b1 R 5b2 、-C(=O)OR 5c 、-C(=O)NR 5d1 R 5d2 , C 6-20 Aryl, one or more R 5-1-1 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 5-1-2 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 3-12 Cycloalkyl, with one or more R 5-1-3 Substituted C 3-12 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 5-1-4 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 5-1-5 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 5-1-6 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms, which are independently selected from O, S and N"; when there are multiple substituents, they may be the same or different;

[0056] R 5-1-1 , R 5-1-2 , R 5-1-3 , R 5-1-4 , R 5-1-5 and R 5-1-6 are independently halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0057] R 5a , R 5b1, R 5b2 , R 5c , R 5d1 and R 5d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0058] The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds:

[0059] N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide,

[0060] N-(1-cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-1-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide.

[0061] In one embodiment, in the structure shown in Formula I,

[0062] A 3 is C;

[0063] A 4 is N;

[0064] A 5 NR 5 ;

[0065]

[0066] R a1 is cyano or C 1-6 alkyl;

[0067] Ring Y is "a 4-12-membered heterocycloalkyl group containing 1 to 3 heteroatoms independently selected from O, S and N" or "a 4-8-membered heterocycloalkenyl group containing 1 to 3 heteroatoms independently selected from O, S and N";

[0068] R 1 for

[0069] R 11 and R 14 Independently for C 1-6 alkyl;

[0070] n is 0, 1 or 2;

[0071] R 2 For cyano, C 3-8 Cycloalkyl or C 1-6alkyl;

[0072] R 3 For one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N";

[0073] R 3-1 is C substituted by one or more halogens 1-6 alkyl;

[0074] R 5 C 1-6 alkyl;

[0075] The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds:

[0076] N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide,

[0077] N-(1-cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-1-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide.

[0078] In one embodiment, the heteroaromatic ring sulfonamide structure compound as shown in Formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound is embodiment 1, embodiment 2 or embodiment 3:

[0079] Scheme 1: In the heteroaromatic sulfonamide structure compound shown in Formula I,

[0080] represents a single bond or a double bond;

[0081] A 3 is C or N;

[0082] A 4 N or CR 4 ;

[0083] A 5 NR 5 or CR 5 ;

[0084]

[0085] R a1 is cyano or C 1-6 alkyl;

[0086] Ring Y is "a 4-12-membered heterocycloalkyl group containing 1 to 3 heteroatoms independently selected from O, S and N" or "a 4-8-membered heterocycloalkenyl group containing 1 to 3 heteroatoms independently selected from O, S and N";

[0087] R 1 for

[0088] R 11 , R 12 , R 13 , R 14 , R 15 and R 16 Independently for C 1-6 Alkyl, with one or more R 1-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl, with one or more R 1-2 Substituted C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 1-3 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, one or more R 1-4 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 1-5 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 1-6 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 1-7 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N";

[0089] R 1-1 , R 1-2 , R 1-3 , R 1-4 , R 1-5 , R 1-6 and R 1-7 For halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 1a、-NR 1b1 R 1b2 、-C(=O)OR 1c 、-C(=O)NR 1d1 R 1d2 、-S(O) 2 NR 1e1 R 1e2 、-S(O) 2 R 1f , C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, or "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; when there are multiple substituents, they may be the same or different;

[0090] R 1a , R 1b1 , R 1b2 , R 1c , R 1d1 , R 1d2 , R 1e1 , R 1e2 and R 1f are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0091] n is 0, 1, 2, 3, 4, 5 or 6;

[0092] R 2 For halogen, hydroxyl, cyano, oxo, C 1-6 Alkyl, with one or more R 2-1 Substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 2a 、-NR 2b1 R 2b2 、-C(=O)OR 2c or -C(=O)NR 2d1 R 2d2 ; or, when n is 2, 3, 4, 5 or 6, any two R 2 connected to each other, independently together with the atoms in the ring to which they are connected, form a 3-8 membered carbocyclic ring, or a 3-8 membered heterocyclic ring containing 1-3 heteroatoms, which are independently selected from O, S and N;

[0093] R 2-1 For halogen, cyano, C 1-6 Alkyl-O-, hydroxyl, -C(=O)R 22a 、-NR 22b1 R 22b2 、-C(=O)OR 22c or -C(=O)NR 22d1 R 22d2 ;

[0094] R 2a , R 2b1 , R 2b2 , R 2c , R 2d1 , R 2d2 , R 22a , R 22b1 , R 22b2 , R 22c , R 22d1 and R 22d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0095] R 3 is a 5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N, or is replaced by one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N";

[0096] R 3-1 For halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C substituted by one or more halogens 1-6 Alkyl, with one or more -OC 1-6 Alkyl substituted C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC substituted by one or more halogens 1-6 Alkyl, pentafluorinated sulfur, or -SC substituted by one or more halogens 1-6 Alkyl; when there are multiple substituents, they may be the same or different;

[0097] R 4 For hydrogen, halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0098] R 5 For hydrogen, C 1-6 Alkyl, or one or more R 5-1 Substituted C1-6 alkyl;

[0099] R 5-1 For deuterium, halogen, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, Hydroxyl, -OC 1-6 Alkyl, -C(=O)R 5a 、-NR 5b1 R 5b2 、-C(=O)OR 5c 、-C(=O)NR 5d1 R 5d2 , C 6-20 Aryl, one or more R 5-1-1 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 5-1-2 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 3-12 Cycloalkyl, with one or more R 5-1-3 Substituted C 3-12 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 5-1-4 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 5-1-5 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 5-1-6 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms, which are independently selected from O, S and N"; when there are multiple substituents, they may be the same or different;

[0100] R 5-1-1 , R 5-1-2 , R 5-1-3 , R 5-1-4 , R 5-1-5 and R 5-1-6 are independently halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0101] R 5a , R 5b1 , R 5b2 , R 5c , R 5d1 and R 5d2 are independently hydrogen, C 1-6Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0102] The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds:

[0103] N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide,

[0104] N-(1-cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-1-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide.

[0105] Scheme 2: The structure of the heteroaromatic ring sulfonamide structure compound shown in Formula I is shown in Formula II:

[0106]

[0107] in, represents a single bond or a double bond;

[0108] A 1 is C, CH or N;

[0109] A 3 is C or N;

[0110] A 4 N or CR 4 ;

[0111] A 5 NR 5 or CR 5 ;

[0112]

[0113] R a1 is cyano or C 1-6 alkyl;

[0114] R 1 for

[0115] R 11 , R 12 , R 13 , R 14 , R 15 and R 16 Independently for C 1-6 Alkyl, with one or more R 1-1 Substituted C 1-6 Alkyl, C3-10 Cycloalkyl, with one or more R 1-2 Substituted C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 1-3 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, one or more R 1-4 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 1-5 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 1-6 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 1-7 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N";

[0116] R 1-1 , R 1-2 , R 1-3 , R 1-4 , R 1-5 , R 1-6 and R 1-7 For halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 1a 、-NR 1b1 R 1b2 、-C(=O)OR 1c 、-C(=O)NR 1d1 R 1d2 、-S(O) 2 NR 1e1 R 1e2 、-S(O) 2 R 1f , C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8Cycloalkenyl, or "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; when there are multiple substituents, they may be the same or different;

[0117] R 1a , R 1b1 , R 1b2 , R 1c , R 1d1 , R 1d2 , R 1e1 , R 1e2 and R 1f are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0118] n is 0, 1, 2, 3, 4, 5 or 6;

[0119] R 2 For halogen, hydroxyl, cyano, oxo, C 1-6 Alkyl, with one or more R 2-1 Substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 2a 、-NR 2b1 R 2b2 、-C(=O)OR 2c or -C(=O)NR 2d1 R 2d2 ; or, when n is 2, 3, 4, 5 or 6, any two R 2 connected to each other, independently together with the atoms in the ring to which they are connected, form a 3-8 membered carbocyclic ring or a 3-8 membered heterocyclic ring containing 1-3 heteroatoms, which are independently selected from O, S and N;

[0120] R 2-1 For halogen, cyano, C 1-6 Alkyl-O-, hydroxyl, -C(=O)R 22a 、-NR 22b1 R 22b2 、-C(=O)OR 22c or -C(=O)NR 22d1 R 22d2 ;

[0121] R 2a , R 2b1 , R 2b2 , R 2c , R 2d1 , R 2d2 , R22a , R 22b1 , R 22b2 , R 22c , R 22d1 and R 22d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0122] R 3 is a 5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N, or is replaced by one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N";

[0123] R 3-1 For halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C substituted by one or more halogens 1-6 Alkyl, with one or more -OC 1-6 Alkyl substituted C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC substituted by one or more halogens 1-6 Alkyl, pentafluorinated sulfur, or -SC substituted by one or more halogens 1-6 Alkyl; when there are multiple substituents, they may be the same or different;

[0124] R 4 For hydrogen, halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0125] R 5 For hydrogen, C 1-6 Alkyl, or one or more R 5-1 Substituted C 1-6 alkyl;

[0126] R 5-1 For deuterium, halogen, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, Hydroxyl, -OC 1-6 Alkyl, -C(=O)R 5a 、-NR 5b1 R 5b2 、-C(=O)OR 5c 、-C(=O)NR 5d1 R 5d2 , C 6-20 Aryl, one or more R 5-1-1 Substituted C 6-20Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 5-1-2 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 3-12 Cycloalkyl, with one or more R 5-1-3 Substituted C 3-12 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 5-1-4 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 5-1-5 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 5-1-6 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms, which are independently selected from O, S and N"; when there are multiple substituents, they may be the same or different;

[0127] R 5-1-1 , R 5-1-2 , R 5-1-3 , R 5-1-4 , R 5-1-5 and R 5-1-6 are independently halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0128] R 5a , R 5b1 , R 5b2 , R 5c , R 5d1 and R 5d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl;

[0129] The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds:

[0130] N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide,

[0131] N-(1-cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-1-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide.

[0132] Scheme 3: In the structure shown in Formula I,

[0133] A 3 is C;

[0134] A 4 is N;

[0135] A 5 NR 5 ;

[0136]

[0137] R a1 is cyano or C 1-6 alkyl;

[0138] Ring Y is "a 4-12-membered heterocycloalkyl group containing 1 to 3 heteroatoms independently selected from O, S and N" or "a 4-8-membered heterocycloalkenyl group containing 1 to 3 heteroatoms independently selected from O, S and N";

[0139] R 1 for

[0140] R 11 and R 14 Independently for C 1-6 alkyl;

[0141] n is 0, 1 or 2;

[0142] R 2 is cyano or C 1-6 alkyl;

[0143] R 3 For one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N";

[0144] R 3-1 is C substituted by one or more halogens 1-6 alkyl;

[0145] R 5 C 1-6 alkyl;

[0146] The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds:

[0147] N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide,

[0148] N-(1-Cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide.

[0149] In one embodiment, the structure of the heteroaromatic ring sulfonamide structure compound shown in Formula I or II is shown in Formula III,

[0150]

[0151] R a1 is cyano or C 1-6 alkyl;

[0152] R 1 for

[0153] R 11 and R 14 Independently for C 1-6 alkyl;

[0154] n is 0 or 1;

[0155] R 2 C 1-6 alkyl;

[0156] R 3 For one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N";

[0157] R 3-1 is C substituted by one or more halogens 1-6 alkyl;

[0158] R 5 C 1-6 alkyl.

[0159] In one scheme, when n is 1,

[0160] In one scenario, R 1 for

[0161] In one scenario, A 3 For C.

[0162] In one scenario, A 4is N.

[0163] In one scenario, A 5 NR 5 .

[0164] In one plan,

[0165] In one scenario, R a1 is cyano or C 1-6 alkyl.

[0166] In one scheme, when R a1 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 1-1 , R 1-2 , R 1-3 , R 1-4 , R 1-5 , R 1-6 , R 1-7 , R 1a , R 1b1 , R 1b2 , R 1c , R 1d1 , R 1d2 , R 1e1 , R 1e2 , R 1f , R 2 , R 2-1 , R 2-2 , R 2a , R 2b1 , R 2b2 , R 2c , R 2d1 , R 2d2 , R 22a , R 22b1 , R 22b2 , R 22c , R 22d1 , R 22d2 , R 3-1 , R 4 , R 5 , R 5-1 , R 5-1-1 , R 5-1-2 , R 5-1-3 , R 5-1-4 , R 5-1-5 , R 5-1-6 , R 5a , R 5b1 , R 5b2 , R 5c , R5d1 and R 5d2 The definition of C 1-6 When the C 1-6 Alkyl is C 1-4 Alkyl, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl.

[0167] In one scenario, R a1 It is cyano or methyl.

[0168] In one scenario, R 1 for

[0169] In one embodiment, n is 0, 1 or 2.

[0170] In one scenario, R 2 For cyano, C 3-8 Cycloalkyl or C 1-6 alkyl.

[0171] In one scenario, R 2 It is cyano, cyclopropyl, ethyl, n-propyl or methyl.

[0172] In one scheme, when R 3 is a 5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N, or is replaced by one or more R 3-1 When the substituted “5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N”, the R 3 It is a "5-6 membered heteroaryl group containing 1-3 heteroatoms which are independently selected from S and N".

[0173] In one scheme, when R 3-1 is C substituted by one or more halogens 1-6 When alkyl, the R 3-1 C is substituted with two or three halogens 1-2 Alkyl, for example, two or three fluorine-substituted methyl.

[0174] In one scenario, R 3 for

[0175] In one scenario, R 5 It is methyl.

[0176] In a certain embodiment, when ring Y is a "4-12 membered heterocycloalkyl group containing 1-3 heteroatoms independently selected from O, S and N", the ring Y is a "4-8 membered heterocycloalkyl group containing 1-2 heteroatoms independently selected from O, S and N", for example, a 4-6 membered heterocycloalkyl group containing 2 heteroatoms N.

[0177] In a certain embodiment, when ring Y is "a 4-8 membered heterocycloalkenyl group containing 1-3 heteroatoms independently selected from O, S and N", the ring Y is "a 4-6 membered heterocycloalkenyl group containing 1-3 heteroatoms independently selected from O, S and N", for example, a 4-6 membered heterocycloalkenyl group containing 1 heteroatom N.

[0178] In one embodiment, ring Y is

[0179] In one plan,

[0180] In one embodiment, among the heteroaromatic sulfonamide structure compound shown in Formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound, the compound shown in Formula I is any of the following structures:

[0181]

[0182]

[0183]

[0184]

[0185] The present invention also provides a pharmaceutical composition, which comprises substance A and pharmaceutical excipients; the substance A is a therapeutically effective amount of the above-mentioned heteroaromatic ring sulfonamide structure compound as shown in formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound.

[0186] The present invention also provides an application of a substance A in the preparation of a PARG inhibitor, wherein the substance A is the heteroaromatic ring sulfonamide structure compound shown in Formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or an isotope compound thereof.

[0187] The present invention also provides a method for inhibiting PARG with substance A, comprising administering to a subject an effective amount of substance A. The substance A is the heteroaromatic ring sulfonamide structure compound shown in formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound.

[0188] The present invention also provides an application of a substance A in the preparation of a drug, wherein the drug is used to treat or prevent PARG-mediated diseases; the substance A is the heteroaromatic ring sulfonamide structure compound shown in Formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or an isotope compound thereof.

[0189] The present invention also provides a method for treating or preventing PARG-mediated diseases using substance A, which comprises administering to a subject an effective amount of substance A. The substance A is the heteroaromatic ring sulfonamide structure compound shown in formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound.

[0190] The present invention also provides a use of a substance A in the preparation of a drug, wherein the drug is used to treat or prevent cancer; the substance A is the above-mentioned heteroaromatic ring sulfonamide structure compound as shown in formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound. The cancer is, for example, one or more of colon cancer, appendix cancer, pancreatic cancer, MYH-related polyposis, blood cancer, breast cancer, endometrial cancer, gallbladder cancer, bile duct cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head or neck cancer, bone cancer, skin cancer, rectal cancer, liver cancer, esophageal cancer, gastric cancer, thyroid cancer, bladder cancer, lymphoma, leukemia and melanoma.

[0191] The present invention also provides a method for treating or preventing cancer with substance A, which comprises administering an effective amount of substance A to a subject. The substance A is the heteroaromatic ring sulfonamide structure compound shown in formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound. The cancer is, for example, one or more of colon cancer, appendix cancer, pancreatic cancer, MYH-related polyposis, blood cancer, breast cancer, endometrial cancer, gallbladder cancer, bile duct cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head or neck cancer, bone cancer, skin cancer, rectal cancer, liver cancer, esophageal cancer, gastric cancer, thyroid cancer, bladder cancer, lymphoma, leukemia and melanoma.

[0192] The term "pharmaceutically acceptable salt" refers to a salt prepared from a compound of the present invention and a relatively nontoxic, pharmaceutically acceptable acid or base. When the compound of the present invention contains a relatively acidic functional group, a base addition salt can be obtained by contacting a neutral form of such compound with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include, but are not limited to, lithium salts, sodium salts, potassium salts, calcium salts, aluminum salts, magnesium salts, zinc salts, bismuth salts, ammonium salts, and diethanolamine salts. When the compound of the present invention contains a relatively basic functional group, an acid addition salt can be obtained by contacting a neutral form of such compound with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent. The pharmaceutically acceptable acid includes an inorganic acid, and the inorganic acid includes, but is not limited to, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, phosphoric acid, phosphorous acid, sulfuric acid, and the like. The pharmaceutically acceptable acid includes organic acids, including but not limited to acetic acid, propionic acid, oxalic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, salicylic acid, tartaric acid, methanesulfonic acid, isonicotinic acid, acid citric acid, oleic acid, tannic acid, pantothenic acid, bitartrate, ascorbic acid, gentisic acid, fumaric acid, gluconic acid, sugar acid, formic acid, ethanesulfonic acid, pamoic acid (i.e., 4,4'-methylene-bis(3-hydroxy-2-naphthoic acid)), amino acids (e.g., glutamic acid, arginine), etc. When the compounds of the present invention contain relatively acidic and relatively basic functional groups, they can be converted into base addition salts or acid addition salts. For details, see Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66:1-19 (1977), or Handbook of Pharmaceutical Salts: Properties, Selection, and Use (P. Heinrich Stahl and Camille G. Wermuth, ed., Wiley-VCH, 2002).

[0193] In the present invention, when there are plural substituents, they may be the same or different.

[0194] The term "stereoisomer" refers to isomers caused by the same order of interconnection of atoms or atomic groups in a molecule but different spatial arrangements, such as cis-trans isomers, optical isomers or atropisomers, etc. These stereoisomers can be separated, purified and enriched by asymmetric synthesis methods or chiral separation methods (including but not limited to thin layer chromatography, rotary chromatography, column chromatography, gas chromatography, high pressure liquid chromatography, etc.), and can also be obtained by chiral separation by bonding (chemical bonding, etc.) or salt formation (physical bonding, etc.) with other chiral compounds.

[0195] The term "tautomer" refers to functional group isomers resulting from the rapid movement of an atom in two positions in a molecule. For example, acetone and 1-propene-2-ol can be interconverted by the rapid movement of hydrogen atoms on oxygen and α-carbon.

[0196] The term "isotopic compound" refers to a compound in which one or more atoms are replaced by one or more atoms having a specific atomic mass or mass number. Examples of isotopes that can be incorporated into the compounds of the invention include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur, and chlorine (e.g., 2H, 3H, 13C, 14C, 15N, 18O, 17O, 18F, 35S, and 36Cl). The isotopic compounds of the invention can generally be prepared by substituting an isotopically labeled reagent for a non-isotopically labeled reagent according to the methods described herein.

[0197] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0198] The term "alkyl" refers to a straight or branched chain alkyl group having a specified number of carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.

[0199] The terms "cycloalkyl" and "carbocycle" refer to a ring having a specified number of carbon atoms (e.g., C 3 ~C 6 ) , a saturated cyclic group consisting only of carbon atoms, which is a monocyclic, bridged or spirocyclic ring. Cycloalkyl includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

[0200] The term "aryl" refers to an aromatic group consisting of carbon atoms, each ring having aromatic properties, such as phenyl or naphthyl.

[0201] The term "heteroaryl" refers to a cyclic group having a specified number of ring atoms (e.g., 5 to 12 members), a specified number of heteroatoms (e.g., 1, 2, or 3), a specified type of heteroatoms (one or more of N, O, and S), which is monocyclic or polycyclic, and at least one ring is aromatic (in accordance with Huckel's rule). The heteroaryl group is connected to other fragments in the molecule through an aromatic ring or a non-aromatic ring. Heteroaryl includes, but is not limited to, furanyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, indolyl, and the like.

[0202] The term "hydroxy" refers to an -OH group.

[0203] The term "cyano" refers to a -CN group.

[0204] The "C" that determines the carbon number range x1 -C y1 " (x1 and y1 are integers), such as "C x1 -C y1 "Alkyl, "C x1 -C y1 "Cycloalkyl", "C x1 -C y1 "Cycloalkenyl", "C x1 -C y1 "alkoxy", "C x1 -C y1 "Alkenyl, "C x1 -C y1 "Alkynyl, "C x1 -C y1 "Aryl, "C x1 -C y1 "heteroaryl" or "C x1 -C y1 "Heterocyclic" means the number of carbon atoms not including the substituents, for example, C 1 -C 6 Alkyl refers to an unsubstituted C 1 -C 6 alkyl.

[0205] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0206] The reagents and raw materials used in the present invention are commercially available.

[0207] The positive and progressive effect of the present invention is that the present invention provides a heteroaromatic ring sulfonamide structure compound, a pharmaceutical composition and application thereof, and the heteroaromatic ring sulfonamide compound has a good inhibitory effect on PARG and is expected to be used for the treatment and / or prevention of various diseases related to PARG. DETAILED DESCRIPTION

[0208] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0209] In the present invention, room temperature refers to ambient temperature, which is 10° C. to 35° C. Overnight refers to 8 to 15 hours. Reflux refers to the reflux temperature of the solvent under normal pressure.

[0210] The solvents involved in the following examples are all analytically pure or chromatographically pure. When the solvents involved in the following examples are mixed solvents, unless otherwise specified, they are all volume ratios.

[0211] The following is a list of abbreviations used in the examples:

[0212] DCM Dichloromethane

[0213] DMF N,N-Dimethylformamide

[0214] EA Ethyl acetate

[0215] DMSO Dimethyl sulfoxide

[0216] DMAP 4-dimethylaminopyridine

[0217] DIPEA Diisopropylethylamine

[0218] TEA Triethylamine

[0219] NCS N-Chlorosuccinimide

[0220] Pd(dtbpf)Cl 2 1,1'-Bis(di-tert-butylphosphino)ferrocenedichloropalladium

[0221] Pd(Amphos)Cl 2 Di-tert-butyl-(4-dimethylaminophenyl)phosphine palladium(II) dichloride

[0222] Pd 2 (dba) 3 Tris(dibenzylideneacetone)dipalladium

[0223] m-CPBA m-Chloroperbenzoic acid

[0224] Xantphos 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene

[0225] RuPhos 2-Bicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl

[0226] THF Tetrahydrofuran

[0227] THP 2-Tetrahydropyran

[0228] TFA Trifluoroacetic acid

[0229] Tf trifluoromethanesulfonyl

[0230] SEMCl 2-(Trimethylsilyl)ethoxymethyl chloride

[0231] DHP 3,4-Dihydro-2H-pyran

[0232] DBH Dibromohydantoin

[0233] Boc tert-Butyloxycarbonyl

[0234] RuPhos Pd G3 Methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II)

[0235] NMM N-Methylmorpholine

[0236] [Ir(COD)OMe] 2 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer

[0237] Example 1 Synthesis route of compound 1

[0238]

[0239] Synthesis of compound 1-h

[0240] Compound 1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester (200 mg, 0.96 mmol) was dissolved in dichloromethane (20 mL), triethylamine (194 mg, 1.92 mmol) was added thereto, isopropylsulfonyl chloride (164 mg, 1.15 mmol) was added dropwise under ice bath, and the reaction solution was stirred at room temperature for 2 hours. Water (100 mL) was added to the reaction solution, and dichloromethane (100 mL) was used for extraction. The organic phase was washed with saturated brine (100 mL), dried over sodium sulfate, the desiccant was filtered off, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography (mobile phase, PE / EA 1 / 1) to obtain compound 1-h (120 mg, 40%). LC-MS (ESI): m / z 316.2 (M+H) + .

[0241] Synthesis of compound 1-g

[0242] At room temperature, cesium carbonate (8.39 g, 25.75 mmol) and iodomethane (1.60 mL, 25.75 mmol) were added to a solution of methyl 6-fluoro-1H-indazole-3-carboxylate (2.5 g, 12.88 mmol) in DMF (10 mL). After addition, the reactants were stirred at room temperature overnight. After the reaction was completed, ethyl acetate was added to dilute, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The product was separated and purified by a rapid separation column (mobile phase: ethyl acetate / petroleum ether 0% to 50%) to obtain compound 1-g (1.4 g, 52%) as a white solid. LC-MS (ESI): m / z=209.2[M+H] + ; 1 H NMR (DMSO-d 6 ,400MHz): δ8.07(1H,dd,J=8.8,5.2Hz),7.72(1H,dd,J=9.6,2.0Hz),7.24(1H,td,J=9.2,2.0Hz),4.13(3H,s),3.92(3H,s).

[0243] Synthesis of compound 1-f

[0244] 1-g (1.4 g, 6.72 mmol), hydrazine hydrate (5 mL) and ethanol (50 mL) were added to the reaction flask, and the mixture was stirred at 60 ° C overnight. After the reaction was completed, the reactants were cooled to room temperature and concentrated to remove the organic solvent. The crude product was washed with ethanol (20 mL), filtered, and the filter cake was dried to obtain 1-f (1.2 g, 86%). LC-MS (ESI): m / z = 209.1 [M+H] + .

[0245] Synthesis of compound 1-e

[0246] Under an ice-water bath, 1-f (1.2 g, 5.76 mmol), triethylamine (2.4 mL, 17.29 mmol) and dichloromethane (20 mL) were added to the reaction flask and stirred for 10 minutes. Trifluoroacetic anhydride (1.2 mL, 8.65 mmol) was then slowly added dropwise to the reaction solution and stirred at 0 ° C for 3 hours under nitrogen protection. After the reaction was completed, the reaction solution was washed with saturated sodium bisulfate aqueous solution (40 mL * 2). The organic phase was concentrated. The crude product was dissolved in ethyl acetate (5 mL) and slowly added dropwise to stirred petroleum ether (200 mL). Filter and dry to obtain a white solid compound 1-e (1.5 g, 86%). LC-MS (ESI): m / z = 305.1 [M + H] + .

[0247] Synthesis of compound 1-d

[0248] At room temperature, 1-e (1.5 g, 4.93 mmol), Lawesson's reagent (4.99 g, 12.33 mmol) and toluene (30 mL) were added to the reaction flask, and the mixture was stirred at 75 ° C for 12 hours under nitrogen protection. After the reaction was completed, saturated sodium carbonate aqueous solution (15 mL) was added to quench the reaction. The mixed solution was stirred at 35 ° C for 3 hours. The liquids were separated and the organic phase was concentrated. Ethanol (18 mL) and water (1.5 mL) were added to the crude product and stirred at 85 ° C for 3 hours. Cool to 0 ° C, filter, and dry the filter cake to obtain compound 1-d (1.3 g, 87%) as a white solid. LC-MS (ESI): m / z=303.0[M+H] + .

[0249] Synthesis of compound 1-c

[0250] Under ice bath, add chlorosulfonic acid (5.5 mL) to the reaction bottle and stir at 0°C for 10 minutes. Then slowly add 1-d (0.5 g, 1.65 mmol) to the reaction solution. After the addition, remove the ice bath, heat to 65°C under nitrogen protection and stir for 18 hours. After the reaction, cool the reaction solution to room temperature, then slowly add the reaction solution to ice water (100 mL), filter, and dry the filter cake to obtain white solid compound 1-c (550 mg, 83%). LC-MS (ESI): m / z=401.0[M+H] + .

[0251] Synthesis of compound 1-b

[0252] 1-c (550 mg, 1.37 mmol), dichloromethane (20 mL), dibromohydantoin (471 g, 1.65 mmol) were added to the reaction bottle and stirred for 10 minutes in an ice-water bath. Then trifluoromethanesulfonic acid (3 mL) was slowly added. After the addition, the mixed solution was warmed to room temperature and stirred for 6 hours. After the reaction was completed, the reaction solution was added to ice water (100 mL) to quench and extracted with dichloromethane (50 mL*2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was slurried with (PE / EA=3 / 1) (30 mL) and filtered to obtain 1-b (500 mg, 76%) as a khaki solid. LC-MS (ESI): m / z=479.0[M+H] + .

[0253] Synthesis of compound 1-a

[0254] In an ice-water bath, a mixture of 1-amino-1-cyclopropylnitrile hydrochloride (247 mg, 2.09 mmol) and pyridine (2 mL) was stirred for half an hour. Then a solution of 1-b (500 mg, 1.04 mmol) in dichloromethane (20 mL) was added. After the addition, the mixture was stirred at room temperature for 3 hours. After the reaction was completed, the solvent was removed by concentration under reduced pressure, and saturated sodium bisulfate was added until pH 4-5. The mixture was extracted with ethyl acetate (30 mL*3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by a rapid separation column (mobile phase: ethyl acetate / petroleum ether: 0% to 100%) to obtain compound 1-a (400 mg, 73%) as a slightly yellow solid.

[0255] Synthesis of compound 1

[0256] 1-a (60 mg, 0.11 mmol), 1-h (54 mg, 0.17 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium dichloride (15 mg, 0.023 mmol), cesium fluoride (52 mg, 0.34 mmol), 1,4-dioxane (9 mL) and H were added to the reaction flask. 2 O (1mL). After nitrogen replacement 3 times, the reaction solution was heated and stirred at 100°C for 5 hours. After the reaction was completed, the reaction solution was cooled to room temperature, concentrated under reduced pressure to remove the organic solvent, and ethyl acetate was added to the residue to dilute it. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by Prep-HPLC to obtain compound 1 (35 mg, 48%) as a white solid. LC-MS (ESI): m / z 634.2 [M+H] + ; 1 H NMR (DMSO-d 6 ,400MHz): δ9.55(1H,s),8.87(1H,d,J=6.8Hz),6.08(1H,s),4.21(3H,s),4.00-4.16(2H,m),3.55-3.69( 2H,m),3.40-3.52(1H,m),2.49-2.59(2H,m),1.41-1.50(2H,m),1.32-1.39(2H,m),1.29(6H,d,J=6.8Hz).

[0257] Example 2 Synthesis route of compound 2

[0258]

[0259] Synthesis of compound 2-d

[0260] Add tetrahydrofuran (70 mL) and water (70 mL) to the reaction flask. Add anhydrous potassium carbonate (12.45 g, 90.09 mmol) under ice bath. Stir the mixture in ice bath for 5 minutes, then add 3-butyne-1-amine hydrochloride (3.17 g, 30.03 mmol). After stirring the reaction solution in ice bath for 10 minutes, add isopropylsulfonyl chloride (7.7 g, 54.00 mmol) dropwise. After the addition, stir the reaction solution in ice bath for 5 minutes, then stir at room temperature for 5 hours. Remove the organic solvent at room temperature, and extract twice with ethyl acetate. Combine the organic phases, wash with water, wash with saturated brine, dry over anhydrous sodium sulfate, filter, and evaporate to dryness to obtain 2-d (3.0 g, yield 57%).

[0261] Synthesis of compound 2-c

[0262] Add 2-d (3.0 g, 17.12 mmol), acetone (20 mL) and anhydrous potassium carbonate (4.73 g, 34.24 mmol) to the reaction flask. Add 3-bromo-2-methylpropene (4.62 g, 34.24 mmol) dropwise at room temperature, and then add tetrabutylammonium iodide (0.36 g, 0.98 mmol). Heat the reaction solution at 60°C and stir overnight. Remove the solvent by vortexing, add ethyl acetate to the residue to dilute, and wash with water. Extract the aqueous phase once with ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, filter, and evaporate to dryness to obtain 2-c (3.9 g, yield 99%).

[0263] Synthesis of compound 2-b

[0264] Add lithium chloride (0.72g, 17.01mmol) to the reaction bottle, heat with an electric heat gun and evacuate for 5 minutes, replace with nitrogen, add anhydrous DMF (40mL), add cuprous chloride (1.68g, 17.01mmol). After nitrogen replacement twice, the mixture was stirred at room temperature for 1 hour. Under nitrogen protection, potassium acetate (1.67g, 17.01mmol) and bis-pinacol borate (4.32g, 17.01mmol) were added. Then 2-c (3.9g, 17.01mmol) was added. After nitrogen replacement twice, the reaction solution was stirred at room temperature overnight. The reaction solution was filtered with diatomaceous earth, and ice water and ethyl acetate petroleum ether mixed solvent (about 3 / 1) were added to the filtrate. Filter with diatomaceous earth again, separate the organic phase from the filtrate, and extract the aqueous phase once with ethyl acetate petroleum ether mixed solvent (about 3 / 1). The organic phases were combined, washed with water, saturated ammonium chloride, saturated brine, dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and purified by column chromatography (mobile phase: petroleum ether / ethyl acetate, 100 / 0 to 80 / 20) to obtain compound 2-b (2.8 g, 46%). 1 H NMR (CDCl 3,400MHz)δ5.84(1H,d,J=3.2Hz),5.67(1H,d,J=3.2Hz),5.02–4.93(2H,m),3.85(2H,s), 3.31–3.20(3H,m),2.44–2.34(2H,m),1.77(3H,s),1.35(6H,d,J=6.8Hz),1.26(12H,s).

[0265] Synthesis of compound 2-a

[0266] Add 2-b (2.8 g, 7.84 mmol) to the reaction flask, blow argon for 1 minute, add anhydrous toluene (160 mL), blow argon for 5 minutes. Add Grubbs 2nd catalyst (0.33 g, 0.39 mmol) and replace with argon 3 times. Heat and stir the reaction solution at 100°C for 24 hours. Add Grubbs 2nd catalyst (0.055 g, 0.065 mmol), replace with argon 3 times, and heat and stir the reaction solution at 100°C for 10 hours. The reaction solution was cooled to room temperature, the solvent was removed by vortexing, ethyl acetate was added to the residue to dilute, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and purified by column (0.5 mL of triethylamine was added to the solution when the silica gel sample was mixed, the silica gel column was moistened with 200 mL of 10% ethyl acetate petroleum ether containing 0.5% triethylamine, and then the column was washed with 200 mL of petroleum ether) (mobile phase: petroleum ether / ethyl acetate, 100 / 0 to 85 / 15), and the obtained sample was slurried with ethyl acetate petroleum ether to obtain compound 2-a (1.0 g, yield 39%). LC-MS (ESI): m / z 330.2 (M+H) + .

[0267] Synthesis of compound 2

[0268] 1-a (50 mg, 0.095 mmol), 2-a (47 mg, 0.14 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium dichloride (12 mg, 0.019 mmol), cesium fluoride (43 mg, 0.28 mmol), 1,4-dioxane (9 mL) and H were added to the reaction flask. 2 O (1mL). After nitrogen replacement 3 times, the reaction solution was heated and stirred at 100°C for 5 hours. After the reaction was completed, the reaction solution was cooled to room temperature, concentrated under reduced pressure to remove the organic solvent, and ethyl acetate was added to the residue for dilution. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by Prep-HPLC to obtain compound 2 (30 mg, 49%). LC-MS (ESI): m / z 648.1 [M+H] + ; 1 H NMR (DMSO-d6 ,400MHz): δ9.54(1H,s),8.88(1H,d,J=6.4Hz),4.16(3H,s),3.91-4.07(2H,m),3.53-3.68(2H, m),3.41-3.53(1H,m),2.37-2.51(2H,m),1.50(3H,s),1.32-1.48(4H,m),1.29(6H,d,J=6.4Hz).

[0269] Example 3 Synthesis route of compound 3

[0270]

[0271] Synthesis of compound 3-e

[0272] At room temperature, compound 1-f (900 mg, 4.32 mmol) was suspended in 20 mL of anhydrous DCM. Under an ice-water bath, triethylamine (1.80 mL, 12.97 mmol) was added, and then difluoroacetic anhydride (806 uL, 6.48 mmol) was added dropwise. The reaction mixture was stirred for 2 hours under a nitrogen ice-water bath. 100 mL of water was added to the reaction solution and extracted with DCM (100 mL). The organic phase was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate (100 mL), washed with 10% sodium bisulfate (100 mL), saturated sodium bicarbonate (100 mL), and saturated brine (100 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was dried under vacuum for 1 hour to obtain compound 3-e (1.2 g, 97%). LC-MS (ESI): m / z=287.0[M+H] + .

[0273] Synthesis of compound 3-d

[0274] At room temperature, compound 3-e (1.20 g, 4.19 mmol) was dissolved in 50 mL of 1,4-dioxane, and Lawesson's reagent (2.54 g, 6.29 mmol) was added. The reaction mixture was stirred at 80 ° C for 5 hours under nitrogen. The reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (100 mL), washed with saturated sodium bicarbonate solution (100 mL*2) and saturated brine (100 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by a rapid separation column (PE / EA=3:1) to obtain compound 3-d (820 mg, 69%). LC-MS (ESI): m / z=285.0[M+H] + .

[0275] Synthesis of compound 3-c

[0276] At room temperature, compound 3-d (820 mg, 2.88 mmol) was dissolved in 15 mL of chlorosulfonic acid. The reaction mixture was stirred at 65 ° C for 18 hours under nitrogen. The reaction solution was cooled to room temperature and slowly added dropwise to an ice-water mixture (200 mL). After the addition was completed, the mixture was extracted with ethyl acetate (100 mL*2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 3-c (1.1 g, 100%). LC-MS (ESI): m / z=383.0[M+H] + .

[0277] Synthesis of compound 3-b

[0278] At room temperature, compound 3-c (1.1 g, 2.87 mmol) was dissolved in 20 mL of DCM, dibromohydantoin (986 mg, 3.45 mmol) was added, and trifluoromethanesulfonic acid (0.56 mL) was added dropwise under an ice-water bath. After the addition was completed, the reaction solution was stirred under an ice-water bath for 10 minutes, then warmed to room temperature and stirred for 3 hours. The reaction solution was slowly poured into ice water (100 mL), extracted with DCM (150 mL), the organic phase was washed with water (100 mL) and saturated brine (100 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was suspended in a mixed solvent of petroleum ether and ethyl acetate (3:1, 20 mL), dispersed with ultrasonic waves for 3 minutes, the mixture was filtered, the filter cake was washed with a mixed solvent (PE / EA=3:1, 10 mL), the solid was collected, and vacuum dried for 30 minutes to obtain compound 3-b (1.3 g, 98%). LC-MS (ESI): m / z = 460.8 [M+H] + .

[0279] Synthesis of compound 3-a

[0280] At room temperature, compound 1-amino-cyclopropylnitrile hydrochloride (334 mg, 2.82 mmol) was dissolved in 10 mL of DCM, pyridine (2.05 mL, 25.34 mmol) was added under ice-water bath, and stirred under ice-water bath for 30 minutes. Compound 3-b (650 mg, 1.41 mmol) was dissolved in DCM (10 mL), added dropwise to the above mixture under ice-water bath, and the reaction solution was warmed to room temperature and stirred overnight. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in 150 mL of ethyl acetate, washed with 10% sodium bisulfate solution (100 mL*2) and saturated brine (100 mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by rapid separation column (EA / PE=0-100%) to obtain compound 3-a (250 mg, 35%). LC-MS (ESI): m / z=507.0[M+H] + .

[0281] Synthesis of compound 3

[0282] At room temperature, compound 3-a (50 mg, 0.099 mmol) was dissolved in 18 mL of 1,4-dioxane, and compound 1-h (47 mg, 0.15 mmol), 1,1′-di-tert-butylphosphinoferrocenepalladium dichloride (13 mg, 0.020 mmol), cesium fluoride (45 mg, 0.30 mmol), and water (2 mL) were added. The reaction mixture was stirred at 100°C under nitrogen for 7 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, 50 mL of water was added to the residue, and extracted with DCM (50 mL*2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by Prep-HPLC (alkali method, NH 4 HCO 3 ) was separated and purified to obtain compound 3 (26.3 mg, 43%). LC-MS (ESI): m / z = 616.1 [M+H] + .

[0283] Example 4 Synthesis route of compound 4

[0284]

[0285] At room temperature, compound 3-a (50 mg, 0.099 mmol) was dissolved in 18 mL of 1,4-dioxane, and compound 2-a (49 mg, 0.15 mmol), 1,1′-di-tert-butylphosphinoferrocenepalladium dichloride (13 mg, 0.020 mmol), cesium fluoride (45 mg, 0.30 mmol), and water (2 mL) were added. The reaction mixture was stirred at 100°C under nitrogen for 7 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, 50 mL of water was added to the residue, and extracted with DCM (50 mL*2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by Prep-HPLC (alkali method, NH 4 HCO 3 ) was separated and purified to obtain compound 4 (7 mg, 11%). LC-MS (ESI): m / z = 630.1 [M+H] + ; 1 H NMR (CDCl 3,400MHz)δ9.19(1H,d,J=6.4Hz),7.11(1H,t,J=53.6Hz),5.76(1H,s),4.15(3H,s),4.13-4.05(1H,m),3.96-3.86(1H,m),3. 85-3.76(1H,m),3.58-3.47(1H,m),3.35-3.23(1H,m),2.59-2.49(2H,m),1.77-1.65(2H,m),1.58(3H,s),1.51-1.37(8H,m).

[0286] Example 5 Synthesis route of compound 5

[0287]

[0288] Synthesis of compound 5-a

[0289] Add 1-b (600 mg, 1.25 mmol) and dichloromethane (100 mL) to the reaction flask, add 1-methylcyclopropylamine hydrochloride (135 mg, 1.25 mmol) and DIPEA (1290 mg, 10.00 mmol) under stirring in an ice-water bath. After the addition, slowly warm the reaction solution to room temperature. Stir at room temperature for 3 hours, add saturated sodium bisulfate aqueous solution (100 mL) to the reaction solution, separate the organic phase, and extract the aqueous phase with dichloromethane (30 mL*2). Combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate to obtain 5-a (420 mg, 65%).

[0290] Synthesis of compound 5

[0291] Add 2-a (50 mg, 0.15 mmol), 5-a (52 mg, 0.10 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene] dichloropalladium (II) (23 mg, 0.04 mmol), cesium fluoride (200 mg, 1.32 mmol), 1,4-dioxane (4 mL) and water (0.8 mL) to the reaction flask, and replace with nitrogen three times. The reaction solution was heated to 100 ° C and stirred for 12 hours. The reaction solution was concentrated under reduced pressure, the residue was washed with ethyl acetate (10 mL*3), the organic phase was concentrated under reduced pressure, and purified by preparative HPLC to obtain compound 5 (11.2 mg, 17%). LC-MS (ESI): m / z 637.1 (M+H) + .

[0292] Example 6 Synthesis route of compound 6

[0293]

[0294] Synthesis of compound 6

[0295] 1-h (32 mg, 0.10 mmol), 5-a (52 mg, 0.10 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene] dichloropalladium (II) (23 mg, 0.04 mmol), cesium fluoride (200 mg, 1.32 mmol), 1,4-dioxane (4 mL) and water (0.8 mL) were added to the reaction flask and replaced with nitrogen three times. The reaction solution was heated to 100 ° C and stirred for 12 hours. The reaction solution was concentrated under reduced pressure, the residue was washed with ethyl acetate (10 mL*3), the organic phase was concentrated under reduced pressure, and purified by preparative HPLC to obtain compound 6 (18.2 mg, 29%). LC-MS (ESI): m / z 623.1 (M+H) + .

[0296] Example 7 Synthesis route of compound 7

[0297]

[0298] Synthesis of compound 7-a

[0299] At room temperature, compound 1-methylcyclopropylamine hydrochloride (303mg, 2.82mmol) was dissolved in 10mL of DCM, triethylamine (1.96mL, 14.08mmol) was added under ice-water bath, and stirred under ice-water bath for 30 minutes. Compound 3-b (650mg, 1.41mmol) was dissolved in DCM (10mL) and added dropwise to the above mixture under ice-water bath. After addition, the reaction solution was warmed to room temperature and stirred for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in 100mL of ethyl acetate, washed with 10% sodium bisulfate solution (100mL*2) and saturated brine (100mL) in turn, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by rapid separation column (EA / PE=0-100%) to obtain compound 7-a (550mg, 79%). LC-MS (ESI): m / z=496.0[M+H] + .

[0300] Synthesis of compound 7

[0301] 7-a (50 mg, 0.10 mmol), 1-h (48 mg, 0.15 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium dichloride (13 mg, 0.020 mmol), cesium fluoride (46 mg, 0.30 mmol), 1,4-dioxane (9 mL) and H were added to the reaction flask. 2O (1mL). After nitrogen replacement 3 times, the reaction solution was heated and stirred at 100°C for 5 hours. After the reaction was completed, the reaction solution was cooled to room temperature, concentrated under reduced pressure to remove the organic solvent, and ethyl acetate was added to the residue for dilution. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification by rapid separation column (mobile phase: ethyl acetate / petroleum ether: 0% to 100%) gave a crude product. The crude product was purified by Prep-HPLC to give compound 7 (30 mg, 49%). LC-MS (ESI): m / z=605.2[M+H] + .

[0302] Example 8 Synthesis route of compound 8

[0303]

[0304] Synthesis of compound 8

[0305] 7-a (50 mg, 0.10 mmol), 2-a (50 mg, 0.15 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium dichloride (13 mg, 0.020 mmol), cesium fluoride (46 mg, 0.30 mmol), 1,4-dioxane (9 mL) and H were added to the reaction flask. 2 O (1mL). After nitrogen replacement 3 times, the reaction solution was heated and stirred at 100°C for 5 hours. After the reaction was completed, the reaction solution was cooled to room temperature, concentrated under reduced pressure to remove the organic solvent, and ethyl acetate was added to the residue for dilution. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification by rapid separation column (mobile phase: ethyl acetate / petroleum ether: 0% to 100%) gave a crude product. The crude product was purified by Prep-HPLC to give compound 8 (15 mg, 24%). LC-MS (ESI): m / z=619.2 [M+H] + .

[0306] Synthetic route of compound 1′

[0307]

[0308] Synthesis of compound 1′-g

[0309] Carefully add trifluoroacetic acid (0.066 mL, 0.86 mmol) to a solution of compound 5-bromo-7-chloro-1H-indazole (2.0 g, 8.64 mmol) in 3,4-dihydro-2H-pyran (25 mL). After the addition, the reactants were heated to 90°C and stirred for 3 hours. After the reaction was completed, the reactants were cooled to room temperature, diluted with ethyl acetate, washed with saturated sodium bicarbonate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The product was separated and purified by a rapid separation column (mobile phase: ethyl acetate / petroleum ether 0% to 50%) to obtain compound 1′-g (2.5 g, 92%). LC-MS (ESI): m / z 314.9 (M+H) + .

[0310] Synthesis of Compound 1′-f

[0311] Add methoxy(cyclooctadiene)iridium dimer (104mg, 0.16mmol), 4,4'-di-tert-butyl-2,2'-bipyridine (85mg, 0.32mmol), biboronic acid pinacol ester (603mg, 2.38mmol) and methyl tert-butyl ether (6mL) to a microwave tube, replace the atmosphere with nitrogen twice and stir at room temperature for 5 minutes. Add 1'-g (0.5g, 1.58mmol) of methyl tert-butyl ether (6mL) solution, replace the atmosphere with nitrogen three times and seal, stir at 85℃ for 3.5 hours. Evaporate the reaction solution to dryness to obtain a borate ester intermediate.

[0312] The borate intermediate was dissolved in toluene (20 mL), and 2-bromo-5-(trifluoromethyl)-1,3,4-thiadiazole (556 mg, 2.38 mmol), palladium acetate (36 mg, 0.16 mmol), Xantphos (183 mg, 0.32 mmol), NMM (0.52 mL, 4.75 mmol) and water (10 mL) were added. The nitrogen was replaced 3 times, and the reaction solution was heated to 40 ° C and stirred for 18 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate, washed with water, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, evaporated, and purified by silica gel column chromatography (mobile phase: ethyl acetate / petroleum ether 0% to 50%) to obtain compound 1′-f (400 mg, 54%). LC-MS (ESI): m / z 466.9 (M+H) + .

[0313] Synthesis of Compound 1′-e

[0314] 1′-f (350 mg, 0.75 mmol), 1,4-dioxane (20 mL), Xantphos (43 mg, 0.075 mmol), DIPEA (0.39 mL, 2.25 mmol) and methyl 3-mercaptopropionate (0.099 mL, 0.90 mmol) were added to the reaction flask, and the atmosphere was replaced with nitrogen twice. Pd 2 (dba) 3 (34 mg, 0.037 mmol), nitrogen replacement 3 times. The reaction solution was heated at 85 ° C and stirred for 2 hours. After the reaction was completed, the reaction solution was cooled to room temperature, evaporated to dryness, and purified by silica gel column chromatography (mobile phase: ethyl acetate / petroleum ether 0% to 50%) to obtain compound 1′-e (350 mg, 92%). LC-MS (ESI): m / z 507.0 (M+H) + .

[0315] Synthesis of compound 1′-d

[0316] At room temperature, TFA (5 mL) was added to a solution of 1′-e (350 mg, 0.69 mmol) in dichloromethane (20 mL). After the addition, the reactants were stirred at room temperature overnight. After the reaction was completed, the solvent was removed by rotary evaporation at room temperature, ethyl acetate was added to dilute, washed with saturated sodium bicarbonate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to obtain compound 1′-d (250 mg, 86%). LC-MS (ESI): m / z 423.0 (M+H) + .

[0317] Synthesis of compound 1′-c

[0318] At room temperature, cesium carbonate (385 mg, 1.18 mmol) and iodomethane (0.096 mL, 1.18 mmol) were added to a DMF (5 mL) solution of 1′-d (250 mg, 0.59 mmol). After the addition, the reactants were stirred at room temperature overnight. After the reaction was completed, ethyl acetate was added to dilute, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The product was separated and purified by a rapid separation column (mobile phase: ethyl acetate / petroleum ether 0% to 50%) to obtain compound 1′-c (200 mg, 77%). LC-MS (ESI): m / z 437.4 (M+H) + .

[0319] Synthesis of compound 1′-b

[0320] Under an ice-water bath, add m-CPBA (237 mg, 1.37 mmol) to a solution of 1′-c (200 mg, 0.46 mmol) in dichloromethane (10 mL). After the addition, the reactant was kept at 0°C and stirred for 1 hour. After the reaction was completed, the solvent was removed by rotary evaporation at room temperature, ethyl acetate was added to dilute, washed with saturated sodium bicarbonate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The crude product was separated and purified by a rapid separation column (mobile phase: ethyl acetate / petroleum ether, 0% to 100%) to obtain compound 1′-b (200 mg, 93%). LC-MS (ESI): m / z 469.0 (M+H) + .

[0321] Synthesis of Compound 1′-a

[0322] Add 1′-b (200 mg, 0.43 mmol), methanol (10 mL) and dichloromethane (10 mL) to the reaction flask. Add sodium methoxide (69 mg, 1.28 mmol) in an ice-water bath. Stir the reaction in an ice-water bath for 1 hour. Add 1-amino-1-cyclopropylnitrile hydrochloride (202 mg, 1.70 mmol) in an ice-water bath. Remove the organic solvent at room temperature and dry with an oil pump for 30 minutes. Add 1-amino-1-cyclopropylnitrile hydrochloride (51 mg, 0.43 mmol) and DMF (10 mL). Add triethylamine (0.73 mL, 0.85 mmol) and NCS (171 mg, 1.28 mmol) in an ice-water bath. Stir the reaction solution in an ice-water bath for 1 hour. Add the reaction solution into ice water and extract twice with ethyl acetate. The organic phase was washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and evaporated to dryness, and purified by column chromatography (PE / EA=3 / 1, 1 / 1) to obtain 1′-a (103 mg, 52%). LC-MS (ESI): m / z 462.9 (M+H) + .

[0323] Synthesis of compound 1′

[0324] 1′-a (46 mg, 0.10 mmol), 1-h (16 mg, 0.05 mmol), dichlorodi-tert-butyl-(4-dimethylaminophenyl)phosphine palladium (II) (18 mg, 0.03 mmol), potassium phosphate (20 mg, 0.09 mmol) were added to a microwave tube, and then 1,4-dioxane (5 mL), water (1 mL) were added, nitrogen was protected, sealed, and stirred at 110°C for 11 hours. The reaction solution was concentrated under reduced pressure and purified by preparative HPLC to obtain compound 1′ (15.9 mg, 76%). LC-MS (ESI): m / z 616.4 (M+H) + ; 1 H NMR (400 MHz, DMSO-d 6):d8.86(1H,d,J=2.0Hz),7.70(1H,d,J=2.0Hz),6.00(1H,s),4.24(3H,s),4.07(2H,d,J=2.4Hz),3.63(2H ,t,J=5.2Hz),3.42-3.54(1H,m),2.57(2H,s),1.40-1.47(2H,m),1.30-1.35(2H,m),1.30(6H,d,J=6.8Hz).

[0325] Synthetic route of compound 2′

[0326]

[0327] Synthesis of compound 2′-h

[0328] Add chlorosulfonic acid (30 mL) to the reaction flask, and add 1-methyl-3-methoxycarbonyl indazole (10 g, 52.58 mmol) in batches within 10 minutes under ice bath. React at room temperature for 5 minutes. Stir the reaction solution at 65°C for 18 hours (add tail gas drying absorption device). Cool the reaction solution to room temperature. Add dropwise to 300 g of ice, extract with ethyl acetate, wash with water, wash with saturated brine, dry with anhydrous sodium sulfate, filter, and evaporate to dryness to obtain 2′-h (13.5 g, 89%).

[0329] Synthesis of compound 2′-g

[0330] Add 2′-h (13.5 g, 46.76 mmol) and dichloromethane (135 mL) to the reaction flask. Add dibromohydantoin (13.37 g, 46.76 mmol) under ice bath. Add trifluoromethanesulfonic acid (5 mL) dropwise to the suspension. Stir the reaction solution in ice bath for 10 minutes and then stir at room temperature for 1.5 hours. Add trifluoromethanesulfonic acid (5 mL) dropwise to the suspension. Add dichloromethane (60 mL). Stir the reaction solution at room temperature for 1.5 hours. Add ice water to the reaction solution, extract twice with ethyl acetate, wash twice with water, wash with saturated brine, dry with anhydrous sodium sulfate, filter, evaporate to dryness and purify by column (mobile phase: petroleum ether / ethyl acetate 100:0~60:40) to obtain the product 2′-g (10.1 g, 59%).

[0331] Synthesis of compound 2′-f

[0332] Add 1-amino-1-cyclopropylnitrile hydrochloride (7.05 g, 59.46 mmol), pyridine (35 mL) and a small amount of 3A molecular sieves to the reaction flask. Stir in an ice bath for 5 minutes. Add a dry solution of 2′-g (10.1 g, 27.48 mmol) in dichloromethane (70 mL) containing molecular sieves dropwise within 5 minutes of the ice bath. React in an ice bath for 10 minutes and then react at room temperature for 2 hours. Rotate to remove the solvent. Add ice water and solid sodium bisulfate to pH = 6-7, add petroleum ether, filter, wash the filter cake with sodium bisulfate, water, and petroleum ether. Extract the aqueous phase with ethyl acetate, wash the extract with water, evaporate to dryness, slurry with ethyl acetate and petroleum ether, combine the solids, and dry in vacuo to obtain 2′-f (11.3 g, 100%). LC-MS (ESI): m / z 412.9 (M+H) + .

[0333] Synthesis of compound 2′-e

[0334] 2′-f (11.3 g, 27.34 mmol) and dichloromethane (150 mL) were added to the reaction flask. Triethylamine (12.5 mL, 89.93 mmol) was added under ice bath and stirred for 10 minutes. SEMCl (8.0 mL, 45.20 mmol) was added dropwise under ice bath and stirred for 10 minutes. Stir in water bath at room temperature for 1.5 hours. The solvent was removed by vortexing at room temperature, water and ethyl acetate were added, the mixture was filtered after sufficient stirring, the filtrate was separated, the aqueous phase was extracted once with ethyl acetate, the organic phases were combined, washed with water, washed with saturated brine, and evaporated to obtain 2′-e (14.8 g, 100%). LC-MS (ESI): m / z 560.1 (M+NH 4 ) + .

[0336] Synthesis of compound 2′-d

[0337] Add 2′-e (14.8 g, 27.23 mmol), anhydrous ethanol (150 mL) and hydrazine hydrate (10 mL, 206.15 mmol) to the reaction flask. Heat the reaction solution at 52°C and stir for 7 hours. Cool the reaction solution to room temperature. Remove the solvent at room temperature, add ice water, extract twice with ethyl acetate, wash with water, wash with saturated brine, dry with anhydrous sodium sulfate, filter and evaporate to obtain 2′-d (14.5 g, 98%). LC-MS (ESI): m / z 1084.8 (2M+H) + .

[0338] Synthesis of compound 2′-c

[0339] Add 2′-d (14.5 g, 26.68 mmol) and dichloromethane (150 mL) to the reaction flask. Add triethylamine (5.19 mL, 37.35 mmol) dropwise under ice bath. Stir in ice bath for 5 minutes. Add difluoroacetic anhydride (3.25 mL, 28.01 mmol) dropwise under ice bath. Stir the reaction solution in ice bath for 1 hour. Add methanol (2.5 mL), stir from ice bath to room temperature for 20 minutes. Rotate to remove the solvent at room temperature. Add water and ethyl acetate to the reaction flask, separate the liquids, extract the aqueous phase once, combine the organic phases, wash with water, wash with saturated brine, dry with anhydrous sodium sulfate, filter, evaporate to dryness and purify through column (mobile phase: petroleum ether / ethyl acetate, 100 / 0 to 60 / 40) to obtain 2′-c (13.2 g, 80%). LC-MS (ESI): m / z 638.0 (M+NH 4 ) + .

[0340] Synthesis of compound 2′-b

[0341] 2′-c (11.3 g, 18.18 mmol), Lawesson reagent (17.75 g, 43.89 mmol) and THF (200 mL) were added to the reaction flask. The reaction solution was heated and stirred at 80°C under argon protection for 10 hours. Cool to room temperature and remove the solvent. The crude product was diluted with a mixture of ethyl acetate / petroleum ether, washed with sodium bicarbonate aqueous solution 3 times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and evaporated to obtain a crude product, and ammonia methanol / methanol / dichloromethane (1:1:20) solution (200 mL) was added and stirred at room temperature for 2 hours. Evaporate and column purification (mobile phase: petroleum ether / ethyl acetate, 100 / 0 to 70 / 30) to obtain 2′-b (5.8 g, 51%). LC-MS (ESI): m / z 619.0 (M+H) + .

[0342] Synthesis of Compound 2′-a

[0343] Compound 2′-b (50 mg, 0.081 mmol), 1-h (51 mg, 0.16 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (12 mg, 0.016 mmol), potassium carbonate (33 mg, 0.24 mmol) were added to 1,4-dioxane (10 mL) and water (1 mL), and the reaction solution was replaced with nitrogen three times, and then heated and stirred at 100°C for 6 hours. The reaction solution was filtered with diatomaceous earth, water (100 mL) was added to the filtrate, and ethyl acetate (100 mL) was used for extraction. The organic phase was washed with saturated brine (100 mL), dried over sodium sulfate, and the desiccant was filtered off. The filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography (mobile phase, PE / EA 1 / 1) to obtain compound 2′-a (50 mg, 85%). LC-MS (ESI): m / z 728.2 (M+H)+ .

[0344] Synthesis of compound 2′

[0345] Compound 2′-a (50 mg, 0.069 mmol) was dissolved in dichloromethane (4.5 mL), trifluoroacetic acid (1.5 mL) was added thereto in an ice-water bath, and the reaction solution was stirred at room temperature for 2 hours. The dichloromethane was removed by concentration under reduced pressure, and the residue was adjusted to pH 7-8 with saturated sodium bicarbonate solution and extracted with ethyl acetate (50 mL). The organic phase was washed with saturated brine (50 mL), dried over sodium sulfate, the desiccant was filtered off, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by preparative HPLC (alkaline conditions) to obtain compound 2′ (33 mg, 80%). LC-MS (ESI): m / z 598.4 (M+H) + .

[0346] Synthetic route of compound 3′

[0347]

[0348] Synthesis of compound 3′-e

[0349] Referring to the synthetic route of compound 2′-b, 2′-d was used as the raw material, and trifluoroacetic anhydride was used instead of difluoroacetic anhydride to synthesize 3′-e.

[0350] Synthesis of compound 3′-d

[0351] 3′-e (88 mg, 0.14 mmol) and dichloromethane (5 mL) were added to the reaction flask. Trifluoroacetic acid (1 mL) and water (0.1 mL) were added dropwise at room temperature. After the addition, the reaction solution was reacted at room temperature for 3 hours. The reaction solution was concentrated at room temperature to remove the solvent, and dichloromethane was added to the residue to dilute it, washed with saturated sodium bicarbonate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to obtain a crude product. The product was separated and purified by a rapid separation column (mobile phase: petroleum ether / ethyl acetate, 0% to 100%) to obtain compound 3′-d (56 mg, 80%). LC-MS (ESI): m / z 506.9 [M+H] + .

[0352] Synthesis of compound 3′-c

[0353] Add 4-oxopiperidone hydrochloride (2.72 g, 20.06 mmol), acetone (30 mL) and water (15 mL) to the reaction flask. Add anhydrous potassium carbonate (7.21 g, 52.16 mmol) in an ice bath, and then drop 2-propylsulfonyl chloride (3.38 mL, 30.09 mmol). Stir the reaction solution from ice bath to room temperature for 18 hours. Add saturated sodium bicarbonate solution to quench the reaction, extract with dichloromethane 3 times, combine the organic phases, wash once with saturated brine, add anhydrous sodium sulfate and anhydrous magnesium sulfate to dry, filter, evaporate to dryness, and wash the crude product twice with petroleum ether to obtain compound 3′-c (2.7 g, 66%).

[0354] Synthesis of compound 3′-b

[0355] Add N,N-dimethylformamide (3.18mL, 39.46mmol) and dichloromethane (60mL) to the reaction flask. Slowly drop a solution of phosphorus tribromide (2.97mL, 31.57mmol) in dichloromethane (10mL) under ice bath. After addition, stir the reaction solution in ice bath for 1 hour. Add a solution of 3′-c (2.7g, 13.15mmol) in dichloromethane (20mL) under ice bath. After addition, stir the reaction solution at room temperature overnight. Stir the reaction solution in ice bath for 5 minutes, and slowly drop a saturated sodium bicarbonate solution until no bubbles are generated. Separate the liquid, extract the aqueous phase with dichloromethane twice, combine the organic phases, dry over anhydrous sodium sulfate, filter, evaporate to dryness, and purify by column (mobile phase: petroleum ether / ethyl acetate, 100 / 0 to 70 / 30) to obtain compound 3′-b (1.6g, 41%). LC-MS (ESI): m / z 313.1 (M+NH 4 ) + .

[0356] Synthesis of compound 3′-a

[0357] Add 3′-b (330 mg, 1.11 mmol) and anhydrous methanol (10 mL) to the reaction flask. Add sodium borohydride (22 mg, 0.58 mmol) after stirring in an ice bath for 5 minutes. Add sodium borohydride (30 mg, 0.79 mmol) after stirring in an ice bath for 5 minutes. Stir the reaction solution in an ice bath for 1 hour. Add saturated aqueous ammonium chloride solution to the reaction solution, spin off the methanol, and extract with ethyl acetate twice. Wash the organic phase with saturated brine, dry over anhydrous sodium sulfate, filter and evaporate to obtain a crude product. Add anhydrous dichloromethane (10 mL) to the crude product, and add triethylamine (0.55 mL, 3.96 mmol) and methanesulfonyl chloride (0.2 mL, 2.58 mmol) dropwise in an ice bath. After addition, stir the reaction solution in an ice bath for 1 hour. Spin off the solvent, dry with an oil pump, and add anhydrous tetrahydrofuran (10 mL) to the residue. In an ice-salt bath, slowly add lithium aluminum hydride tetrahydrofuran solution (1M, 2.5mL, 2.50mmol) dropwise within 20 minutes. After addition, the reaction solution was stirred in an ice-salt bath for 1 hour. Slowly add sodium sulfate decahydrate solid to the reaction solution to quench the reaction, continue stirring the reaction solution for 15 minutes, add ethyl acetate to dilute the reaction solution, and stir at room temperature for 15 minutes. Filter, evaporate to dryness, and purify by column (mobile phase: petroleum ether / ethyl acetate, 100 / 0 to 80 / 20) to obtain compound 3′-a (95mg, 30%). LC-MS (ESI): m / z 281.9 (M+H) + .

[0358] Synthesis of compound 3′

[0359] Add 3′-a (95 mg, 0.34 mmol), bis-pinacol borate (128 mg, 0.50 mmol), Pd(dppf)Cl into a microwave tube. 2 ·CH 2 Cl 2 (15 mg, 0.018 mmol) and potassium acetate (100 mg, 1.02 mmol). Nitrogen replacement, add 1,4-dioxane (4 mL). Nitrogen replacement 3 times, seal. The reaction solution was heated and stirred at 80 ° C for 20 hours. The reaction solution was cooled to room temperature, and 3′-d (100 mg, 0.20 mmol), Pd(dtbpf)Cl 2 (10 mg, 0.015 mmol), cesium fluoride (200 mg, 1.32 mmol) and water (1 mL). Nitrogen was replaced 3 times and the mixture was sealed. The reaction mixture was heated and stirred at 100 °C for 2 hours. 3′-d (100 mg, 0.20 mmol), Pd(dtbpf)Cl 2(20 mg, 0.031 mmol) and cesium fluoride (120 mg, 0.79 mmol). The reaction mixture was replaced with nitrogen and heated at 100°C with stirring for 5 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed with water, and the aqueous phase was extracted with ethyl acetate once. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and purified by column chromatography (mobile phase: dichloromethane / methanol, 100 / 0 to 97 / 3) to obtain a crude product, which was purified by preparative HPLC (ammonium bicarbonate) to obtain compound 3′ (32 mg, 15%). LC-MS (ESI): m / z 630.1 (M+H) + ; 1 H NMR (DMSO-d 6 ,400MHz): δ9.26(1H,bs),8.87(1H,d,J=2.0Hz),7.64(1H,d,J=1.6Hz),4.19(3H,s),4.01–3.88(2H,m),3.68–3.51(2H, m),3.49(1H,q,J=6.8Hz),1.47(3H,s),2.50–2.42(2H,m),1.45–1.39(2H,m),1.38–1.32(2H,m),1.30(6H,d,J=6.7Hz).

[0360] Synthesis route of compound 9

[0361]

[0362] Synthesis of compound 9-a

[0363] Compound 1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester (100 mg, 0.48 mmol) was dissolved in dichloromethane (5 mL), diisopropylethylamine (185 mg, 1.43 mmol) was added thereto, the system was cooled to 0°C, isobutyryl chloride (61 mg, 0.57 mmol) was added thereto dropwise, after the addition was completed, the reaction was stirred at room temperature for 2 hours, saturated sodium bicarbonate solution (10 mL) was added to the reaction solution, extracted twice with dichloromethane (50 mL), dried with sodium sulfate, the desiccant was filtered, and the crude product was obtained by rotary evaporation under reduced pressure. The crude product was purified by column chromatography (mobile phase, PE / EA=1 / 1 to 1 / 5) to obtain compound 9-a (75 mg, 56%). LC-MS (ESI): m / z 280.2 (M+H) + .

[0364] Synthesis of compound 9

[0365] At room temperature, compound 3-a (50 mg, 0.099 mmol) was dissolved in 18 mL of 1,4-dioxane, and compound 9-a (41 mg, 0.15 mmol), 1,1′-di-tert-butylphosphinoferrocenepalladium dichloride (13 mg, 0.020 mmol), cesium fluoride (45 mg, 0.30 mmol), and water (2 mL) were added. The reaction mixture was stirred at 100°C under nitrogen for 16 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was separated and purified by a rapid separation column (EA / PE = 0-100%) to obtain a crude product, which was then purified by Prep-HPLC (alkali method, NH 4 HCO 3 ) was separated and purified to obtain compound 9 (23.5 mg, 41%). LC-MS (ESI): m / z = 580.2 [M+H] + .

[0366] Synthesis route of compound 10

[0367]

[0368] Synthesis of compound 10

[0369] 1-a (50 mg, 0.095 mmol), 9-a (40 mg, 0.14 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium dichloride (12 mg, 0.019 mmol), cesium fluoride (43 mg, 0.28 mmol), 1,4-dioxane (9 mL) and H were added to the reaction flask. 2 O (1mL). After nitrogen replacement 3 times, the reaction solution was heated and stirred at 100°C for 5 hours. After the reaction was completed, the reaction solution was cooled to room temperature, concentrated under reduced pressure to remove the organic solvent, and ethyl acetate was added to the residue for dilution. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by Prep-HPLC to obtain compound 10 (25 mg, 44%). LC-MS (ESI): m / z 598.1 [M+H] + .

[0370] Synthesis route of compound 11

[0371]

[0372] Synthesis of compound 11

[0373] 7-a (50 mg, 0.10 mmol), 9-a (42 mg, 0.15 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium dichloride (13 mg, 0.020 mmol), cesium fluoride (46 mg, 0.30 mmol), 1,4-dioxane (9 mL) and H 2 O (1mL). After nitrogen replacement 3 times, the reaction solution was heated and stirred at 100°C for 5 hours. After the reaction was completed, the reaction solution was cooled to room temperature, concentrated under reduced pressure to remove the organic solvent, and ethyl acetate was added to the residue to dilute it. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by Prep-HPLC to obtain compound 11 (25 mg, 44%). LC-MS (ESI): m / z 569.1 [M+H] + .

[0374] Synthetic route of compound 4′

[0375]

[0376] Synthesis of compound 4′-a

[0377] Compound 2′-b (55 mg, 0.09 mmol), 9-a (37 mg, 0.13 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (13 mg, 0.02 mmol), potassium carbonate (37 mg, 0.27 mmol) were added to 1,4-dioxane (5 mL) and water (0.5 mL). After the reaction solution was replaced with nitrogen 10 times, the tube was sealed and heated and stirred at 100°C for 6 hours. The reaction solution was cooled to room temperature and vacuum evaporated to obtain a crude product, which was purified by column chromatography (mobile phase, PE / EA=3 / 1 to 1 / 1) to obtain compound 4′-a (60 mg, 98%). LC-MS (ESI): m / z692.1 (M+H) + .

[0378] Synthesis of compound 4′

[0379] Compound 4′-a (70 mg, 0.10 mmol) was dissolved in dichloromethane (4.5 mL), trifluoroacetic acid (1.5 mL) was added thereto at 0°C, and the reaction was stirred at room temperature for 2 hours. The reaction solution was evaporated to remove dichloromethane, the pH was adjusted to 7-8 with saturated sodium bicarbonate solution, extracted with ethyl acetate (100 mL), washed with saturated brine (100 mL), and evaporated under reduced pressure to obtain a crude product, which was purified by HPLC (alkaline conditions) to obtain compound 4′ (30 mg, 53%). LC-MS (ESI): m / z 562.2 (M+H) + .

[0380] Synthesis route of compound 12

[0381]

[0382] Synthesis of compound 12

[0383] 5-a (50 mg, 0.097 mmol), 9-a (41 mg, 0.15 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium dichloride (13 mg, 0.019 mmol), cesium fluoride (44 mg, 0.29 mmol), 1,4-dioxane (9 mL) and H were added to the reaction flask. 2 O (1mL). After nitrogen replacement 3 times, the reaction solution was heated and stirred at 100°C for 5 hours. After the reaction was completed, the reaction solution was cooled to room temperature, concentrated under reduced pressure to remove the organic solvent, and ethyl acetate was added to the residue for dilution. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by Prep-HPLC to obtain compound 12 (5 mg, 9%). LC-MS (ESI): m / z 587.2 [M+H] + .

[0384] Synthesis route of compound 13

[0385]

[0386] Synthesis of compound 13-d

[0387] Add triphenyl phosphite (2.3g, 7.41mmol) and anhydrous dichloromethane (20mL) to the reaction flask. Slowly add liquid bromine (1.25g, 7.82mmol) under a dry ice ethyl acetate bath. Keep the reaction solution at this temperature and stir for 5 minutes, then add triethylamine (1.15mL, 8.27mmol) and tert-butyl 3-ethyl-4-oxopiperidin-1-carboxylate (1.48g, 6.51mmol). After the addition, stir the reaction solution at this temperature for 1 hour, stir at room temperature for 18 hours, and heat to reflux for 2 hours. Rotate to remove the reaction solvent, add ethyl acetate and petroleum ether (1:2) to the residue, wash with water twice, wash with saturated brine, and dry over anhydrous sodium sulfate. Filter the organic phase, evaporate to dryness, and purify the crude product by column (mobile phase: petroleum ether / ethyl acetate, 100 / 0 to 88 / 12) to obtain 13-d (800mg, 42%).

[0388] Synthesis of compound 13-c

[0389] Add 13-d (800 mg, 2.76 mmol), biboric acid pinacol ester (1400 mg, 5.51 mmol), Pd(dppf)Cl 2(105mg, 0.14mmol), potassium acetate (810mg, 8.25mmol) and anhydrous 1,4-dioxane (12mL). The reaction solution was replaced with nitrogen three times and heated and stirred at 90°C for 6 hours. The reaction solution was cooled to room temperature, the solvent was removed by vortexing, and ethyl acetate was added to dilute. The dilution was washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, evaporated, and the crude product was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate, 100 / 0 to 88 / 12) to obtain compound 13-c (500mg, yield 54%). LC-MS (ESI): m / z 338.2 (M+H) + .

[0390] Synthesis of compound 13-b

[0391] 13-c (500 mg, 1.48 mmol) was added to the reaction flask, followed by dichloromethane (9 mL) and trifluoroacetic acid (3 mL). The mixture was protected with nitrogen and stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure to obtain compound 13-b (360 mg). LC-MS (ESI): m / z 238.2 (M+H) + .

[0392] Synthesis of compound 13-a

[0393] 13-b (360 mg, 1.52 mmol) was added to the reaction flask, followed by dichloromethane (50 mL), triethylamine (154 mg, 1.52 mmol), and isopropylsulfonyl chloride (360 mg, 2.53 mmol). The mixture was protected with nitrogen and stirred at room temperature for 2 hours. The reaction solution was washed with saturated sodium bisulfate (100 mL) and concentrated to give compound 13-a (226 mg, 43%). LC-MS (ESI): m / z 344.2 (M+H) + .

[0395] Synthesis of compound 13

[0396] Add 13-a (55 mg, 0.16 mmol), acetone (4 mL), water (2.0 mL), ammonium acetate (100 mg, 1.30 mmol) and sodium periodate (100 mg, 0.47 mmol) to the reaction flask. Stir the reaction solution at room temperature for 24 hours and then heat and stir at 60 ° C for 18 hours. Cool the reaction solution to room temperature, add ethyl acetate and a small amount of sodium bisulfate solid, separate the liquids, and extract the aqueous phase with ethyl acetate once. Combine the organic phases, dry over anhydrous sodium sulfate, filter, and evaporate to dryness to obtain crude product A. Add compound 1-a (70 mg, 0.13 mmol), Pd(dtbpf)Cl in a microwave tube. 2(10 mg, 0.015 mmol), a solution of crude product A in 1,4-dioxane (2.5 mL) and a solution of cesium fluoride (82 mg, 0.54 mmol) in water (0.5 mL). The microwave tube was sealed and replaced with nitrogen three times. The reaction solution was heated and stirred at 70°C for 18 hours. The reaction solution was cooled to room temperature, diluted with ethyl acetate, the diluent was washed with water, and the aqueous phase was extracted with ethyl acetate once. The organic phases were combined, evaporated to dryness, and purified by column (mobile phase: petroleum ether / ethyl acetate, 100 / 0 to 40 / 60) to obtain a crude product, which was purified by prep-HPLC (ammonium bicarbonate) to obtain compound 13 (6.3 mg, yield 6.0%). LC-MS (ESI): m / z 662.3 (M+H) + .1H NMR (DMSO-d 6 ,400MHz)δ9.57(1H,bs),8.88(1H,d,J=6.4Hz),4.18(3H,s),4.09–3.95(2H,m),3.67–3.4 4(3H,m),2.48–2.40(2H,m),1.94–1.78(2H,m),1.52–1.27(10H,m),0.85(3H,t,J=7.6Hz).

[0397] Synthetic route of compound 5′

[0398]

[0399] Synthesis of compound 5′-a

[0400] Add 2′-b (80 mg, 0.13 mmol) and dichloromethane (5 mL) to the reaction flask. Add trifluoroacetic acid (1 mL) dropwise at room temperature. After the addition, the reaction solution was reacted at room temperature for 4 hours. The reaction solution was concentrated at room temperature to remove the solvent, and dichloromethane was added to the residue to dilute it, washed with saturated sodium bicarbonate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to obtain a crude product. Separate and purify by rapid separation column (mobile phase: ethyl acetate / (petroleum ether / dichloromethane 4:1), 0% to 100%) to obtain compound 5′-a (50 mg, 79%). LC-MS (ESI): m / z 488.9 [M+H] + .

[0401] Synthesis of compound 5′

[0402] At room temperature, compound 5′-a (200 mg, 0.41 mmol) was dissolved in 36 mL of 1,4-dioxane, and compound 2-a (202 mg, 0.61 mmol), 1,1′-di-tert-butylphosphinoferrocenepalladium dichloride (53 mg, 0.082 mmol), cesium fluoride (186 mg, 1.23 mmol), and water (4 mL) were added. The reaction mixture was stirred at 100°C under nitrogen for 8 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, 50 mL of water was added to the residue, and extracted with DCM (50 mL*2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by Prep-HPLC (alkali method, NH 4 HCO 3 ) was separated and purified to obtain compound 5′ (82 mg, 33%). LC-MS (ESI): m / z=612.1[M+H] + .

[0403] Synthesis of compound 6′

[0404]

[0405] Referring to the synthesis method of compound 13, 3′-d was used to replace 1-a to synthesize compound 6′. LC-MS (ESI): m / z 644.4 (M+H) + . 1 H NMR (DMSO-d 6 ,400MHz)δ9.30(1H,bs),8.88(1H,d,J=1.6Hz),7.63(1H,d,J=1.6Hz),4.22(3H,s),4.11–3.93(2H,m),3.72–3. 60(1H,m),3.59–3.45(2H,m),2.50–2.44(2H,m),1.95–1.76(2H,m),1.50–1.26(10H,m),0.85(3H,t,J=7.6Hz).

[0406] Synthesis of similar compounds:

[0407]

[0408]

[0409] Synthetic route of compound 7′

[0410]

[0411] Synthesis of compound 7′-c

[0412] Add 3′-b (400 mg, 1.35 mmol), bis-pinacol borate (403 mg, 1.59 mmol), Pd(dppf)Cl 2 ·CH 2 Cl 2 (80mg, 0.098mmol) and potassium acetate (396mg, 4.04mmol). Nitrogen replacement, add 1,4-dioxane (10mL). Nitrogen replacement 3 times, seal. The reaction solution is heated and stirred at 80°C for 6 hours. The reaction solution is cooled to room temperature, and the reaction solution (2mL) is taken out and directly proceeded to the next step. The remaining reaction solution is diluted with ethyl acetate, washed once with saturated brine, the aqueous phase is extracted 3 times with ethyl acetate, the organic phases are combined, evaporated to dryness, and oil pump dried to obtain 7′-c crude product (463mg, 100%). LC-MS (ESI): m / z 344.2 (M+H) + .

[0413] Synthesis of compound 7′-b

[0414] Add 7′-c (345 mg, 1.01 mmol), Pd(dtbpf)Cl 2 (41mg, 0.063mmol), 3′-d (335mg, 0.66mmol) and cesium fluoride (340mg, 2.24mmol) in water (2mL). The reaction solution was replaced with nitrogen three times and heated and stirred at 100°C for 2 hours. The reaction solution was cooled to room temperature and diluted with ethyl acetate. The dilution was washed with saturated brine, evaporated to dryness, and the crude product was purified by column (mobile phase: dichloromethane / ethyl acetate, 100 / 0 to 70 / 30) to obtain compound 7′-b (290mg, 68%). LC-MS (ESI): m / z 644.1 (M+H) + .

[0415] Synthesis of compound 7′-a

[0416] Add 7′-b (125 mg, 0.19 mmol), ethyltriphenylphosphine bromide (87 mg, 0.23 mmol), anhydrous potassium carbonate (81 mg, 0.59 mmol) and 1,4-dioxane (6 mL) to a microwave tube. The reaction solution was sealed, replaced with nitrogen three times, and heated and stirred at 80°C for 7 hours. The reaction was not complete, and the reaction solution was heated and stirred at 80°C for 3 hours. The reaction solution was cooled to room temperature, water was added, and extracted twice with ethyl acetate. The organic phases were combined, evaporated to dryness, and purified by column (mobile phase: petroleum ether / ethyl acetate, 100 / 0 to 40 / 60) to obtain compound 7′-a (60 mg, yield 47%). LC-MS (ESI): m / z 656.3 (M+H) + .

[0417] Synthesis of compound 7′

[0418] Add 7′-a (60 mg, 0.092 mmol), ethyl acetate (5 mL) and palladium carbon (10% Pd, containing 40-60% water) (60 mg, 0.56 mmol) to the reaction flask. The reaction solution was replaced with hydrogen and stirred at room temperature for 7 hours. After the reaction solution was replaced with nitrogen, palladium carbon (10% Pd, containing 40-60% water) (30 mg, 0.28 mmol) was added, replaced with hydrogen, and stirred at room temperature for 3 hours. The reaction solution was filtered with diatomaceous earth, the filter cake was washed with dichloromethane / methanol (10:1), the organic phases were combined, spin-dried, and purified by prep-HPLC (ammonium bicarbonate) to obtain 7′ (21.3 mg, yield 35%). LC-MS (ESI): m / z 658.3 (M+H) + .1H NMR (DMSO-d 6 ,400MHz)δ9.31(1H,s),8.88(1H,d,J=2.0Hz),7.61(1H,d,J=1.6Hz),4.21(3H,s),4.07–3.92(2H,m),3.67–3. 45(3H,m),2.50–2.44(2H,m),1.95–1.82(1H,m),1.81–1.70(1H,m),1.48–1.21(12H,m),0.69(3H,t,J=7.3Hz).

[0419] Synthesis of similar compounds:

[0420]

[0421]

[0422] Biological activity test

[0423] PARG enzyme inhibition assay

[0424] Experimental process:

[0425] The PARG in vitro assay was performed in a standard 384-well plate with a total volume of 15 μL. 5 μL of PARG (389-976) (manufactured by Wise Chemical Co., Ltd.) was added to the 384-well plate containing the test compound (different concentrations) at a final concentration of 1.5 pM in a buffer (50 mM Tris-HCL 7.5, 30 mM KCl, 1 mM EDTA, 3 mM DTT, tween-20 0.01%, BSA 0.025%) and incubated at room temperature for 30 minutes. 5 μL of Bio PARylated His-TEV-PARP1 (2-1014) substrate (manufactured by Wise Chemical Co., Ltd.) was added to the above reaction at a final concentration of 12 nM, and the reaction was allowed to react at room temperature for 30 minutes. Add 5 μL of detection reagent, the detection reagent is 50mM Tris-HCL 7.5, 30mM KCl, 1mM EDTA, 3mM DTT, tween-20 0.01%, BSA 0.025% as buffer, composed of 3μM compound PDD00017273 and 9nM Mab anti-6HIS XL665 (Cisbio: 61HISXLA) and 0.9nM streptavidin terbium cryptate (Cisbio: 610SATLA), all three are 3X working concentrations (final concentrations are 1μM, 3nM and 0.3nM, respectively). After incubation in the dark at room temperature for 120 minutes, the TR-FRET signal is measured at Ex 340 and Em 665 and Em 615. The ratio of each well is calculated as Em 665 / Em 615, and the compound inhibition rate is calculated based on the obtained data.

[0426] Table 1 Biochemical activity of PARG, a representative compound of the present invention

[0427]

[0428]

[0429] Cell experiment CTG method to detect the proliferation inhibition of compounds on cell lines

[0430] The relevant experiments were carried out on 384-well plates or 96-well plates. The specific process is as follows:

[0431] Add the cell suspension to be tested to the 384-well or 96-well plate (except the outer wells) (384-well plate: 50 μL; 96-well plate: 100 μL). Place the culture plate in a CO2 incubator overnight, and place HCC1395 and HCC1428 in a 5% CO2 incubator at 37°C overnight. Use the HPD300 microdosing instrument to add the corresponding concentration of compound to each well (through 3-fold dilution, 9-10 concentration gradient compounds are obtained). The cell plate is incubated in a CO2 incubator for 7 days. HCC1395 and HCC1428 are incubated in a 5% CO2 incubator at 37°C. On the day of the test, place the 384-well or 96-well plate at room temperature for 10-30 minutes, then add the CellTiter Glo reagent (384-well plate: 25 μL; 96-well plate: 100 μL) to the 384-well or 96-well plate, shake it for 10 minutes away from light, and incubate it for 10 minutes. Place the culture plate in the Victor NIVO plate reader, use XLFit to draw the drug efficacy inhibition rate curve and calculate the IC 50 value.

[0432] Table 2 Experimental results of representative compounds of the present invention on cell line proliferation inhibition

[0433]

[0434] Kinetic solubility experiments in PBS (pH 7.4)

[0435] Prepare and preheat PBS (pH 7.4) buffer. Add 8 μL of the test compound stock solution (10 mM) to a sample tube containing 792 μL of PBS (pH 7.4) (final concentration of DMSO: 1%). Shake the sample tube at room temperature (1000 rpm) for 1 hour, and centrifuge the sample (10 minutes - 12000 rpm) to precipitate undissolved particles. Then transfer the supernatant to a new tube or plate, and dilute the supernatant 10 times or 100 times with PBS (pH 7.4) buffer. Add 6 μL of 10 mM compound to 194 μL MeOH / ACN (4:1), and dilute with MeOH:ACN (4:1) to prepare the standard curve sample. All samples were analyzed by LC-MS / MS, and the solubility was calculated based on the analysis results.

[0436] Pharmacokinetic study after intravenous and oral administration in mice

[0437] Experimental process:

[0438] After intravenous injection and oral administration of male C57BL / 6J mice or male CD-1 mice, plasma samples were collected at 8-9 time points (e.g., 5min, 15min, 30min, 1h, 2h, 4h, 7h, 24h or 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 24h) through the orbital venous plexus, and the collected blood samples were transferred to microcentrifuge tubes containing EDTA-K2 anticoagulant, centrifuged at 4°C and 4000g for 5min, and the supernatant was taken and stored in a refrigerator at -75°C ± 15°C. LC-MS / MS was used to detect the compound concentrations in plasma at different time points, and WinNonlin software was used to calculate the relevant pharmacokinetic parameters.

[0439] Table 3-1 Pharmacokinetic test results of representative compounds of the present invention

[0440]

[0441] a: Blood samples from male CD-1 mice were mixed and processed for analysis; b: Average values ​​of blood samples from male CD-1 mice were processed separately and analyzed.

[0442] The solvent for intravenous administration was 5% DMSO + 10% Solutol HS-15 + 85% (20% HP-β-CD in water) or 5% DMSO + 15% Solutol HS-15 + 80% Saline; the solvent for oral administration was 0.1% Tween80 + 0.5% MC in water.

[0443] Table 3-2 Pharmacokinetic test results of representative compounds of the present invention

[0444]

[0445]

[0446] Table 3-3 Pharmacokinetic test results of representative compounds of the present invention

[0447]

[0448] a: Blood samples from male CD-1 mice were mixed and processed for analysis. b: Blood samples from male CD-1 mice were processed separately and the average values ​​were obtained.

[0449] The solvent for intravenous administration was 5% DMSO + 10% Solutol HS-15 + 85% (20% HP-β-CD in water) or 5% DMSO + 15% Solutol HS-15 + 80% Saline; the solvent for oral administration was 0.1% Tween80 + 0.5% MC in water.

[0450] The data in Tables 3-1, 3-2 and 3-3 show that the patented compound has obvious advantages in PK parameters compared with the control compound and has a significant improvement in exposure level.

[0451] In vivo efficacy studies

[0452] BALB / c nude mice were injected with estrogen twice a week until the end of the experiment, and 1×10 7 / 100μL (RPMI medium, plus matrix gel at a volume ratio of 1:1) HCC1428 cells. When the average tumor volume reaches 150-200mm 3 The animal weight and tumor size were measured twice a week during the experiment, and the clinical symptoms of the animals were observed and recorded every day. The length (a) and width (b) of the tumor were measured with a vernier caliper, and the tumor volume was calculated as follows: TV = a × b 2 / 2. The tumor growth inhibition rate TGI (%) was calculated based on the tumor volume. The calculation formula is TGI (%) = [1-(T i -T 0 ) / (V i -V 0 )]×100%, where T i is the average tumor volume on the i-th day after the treatment group was divided, T 0 is the average tumor volume when the treatment groups were divided, V i is the average tumor volume of the vehicle control group on day i after grouping, V 0 The mean tumor volume in the vehicle control group.

[0453] Efficacy study of representative compounds in HCC1428 cell subcutaneous transplanted tumor mouse model

[0454]

[0455] Note: The solvent is 0.5% MC + 0.5% Tween80; the average tumor volume reaches 195mm 3 Dosing in each group started at 5:00 p.m.; PO means oral, BID means twice daily.

[0456] The compound of the present invention shows extremely significant drug efficacy in a HCC1428 cell subcutaneous transplantation tumor mouse model.

[0457] Although the specific embodiments of the present invention are described above, it should be understood by those skilled in the art that these are only examples, and various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the protection scope of the present invention is limited by the appended claims.

Claims

1. A heteroaromatic ring sulfonamide structure compound as shown in Formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or an isotope compound thereof: represents a single bond or a double bond; A3 is C or N; A4 is N or CR 4 ; A5 is NR 5 or CR 5 ; for R a1 is cyano or C 1-6 alkyl; Ring Y is "a 4-12-membered heterocycloalkyl group containing 1-3 heteroatoms independently selected from O, S and N" or "a 4-8-membered heterocycloalkenyl group containing 1-3 heteroatoms independently selected from O, S and N"; R 1 for R 11 , R 12 , R 13 , R 14 , R 15 and R 16 Independently for C 1-6 Alkyl, with one or more R 1-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl, with one or more R 1-2 Substituted C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 1-3 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, one or more R 1-4 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 1-5 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 1-6 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 1-7 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; R 1-1 , R 1-2 , R 1-3 , R 1-4 , R 1-5 , R 1-6 and R 1-7 For halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 1a 、-NR 1b1 R 1b2 、-C(=O)OR 1c 、-C(=O)NR 1d1 R 1d2 、-S(O)2NR 1e1 R 1e2 、-S(O)2R 1f , C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, or "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; when there are multiple substituents, they may be the same or different; R 1a , R 1b1 , R 1b2 , R 1c , R 1d1 , R 1d2 , R 1e1 , R 1e2 and R 1f are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; n is 0, 1, 2, 3, 4, 5 or 6; R 2 For halogen, hydroxyl, cyano, oxo, C 1-6 Alkyl, with one or more R 2-1 Substituted C 1-6 Alkyl, C 3-8 Cycloalkyl, with one or more R 2-2 Substituted C 3-8 Cycloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 2a 、-NR 2b1 R 2b2 、-C(=O)OR 2c or -C(=O)NR 2d1 R 2d2 ; or, when n is 2, 3, 4, 5 or 6, any two R 2 connected to each other, independently together with the atoms in the ring to which they are connected, form a 3-8 membered carbocyclic ring, or a 3-8 membered heterocyclic ring containing 1-3 heteroatoms, which are independently selected from O, S and N; R 2-1 and R 2-2 are independently halogen, cyano, C 1-6 Alkyl-O-, hydroxyl, -C(=O)R 22a 、-NR 22b1 R 22b2 、-C(=O)OR 22c or -C(=O)NR 22d1 R 22d2 ; R 2a , R 2b1 , R 2b2 , R 2c , R 2d1 , R 2d2 , R 22a , R 22b1 , R 22b2 , R 22c , R 22d1 and R 22d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 3 is a 5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N, or is replaced by one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms, which are independently selected from O, S and N"; R 3-1 For halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C substituted by one or more halogens 1-6 Alkyl, with one or more -OC 1-6 Alkyl substituted C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC substituted by one or more halogens 1-6 Alkyl, pentafluorinated sulfur, or -SC substituted by one or more halogens 1-6 Alkyl; when there are multiple substituents, they may be the same or different; R 4 For hydrogen, halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 5 For hydrogen, C 1-6 Alkyl, or one or more R 5-1 Substituted C 1-6 alkyl; R 5-1 For deuterium, halogen, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, Hydroxyl, -OC 1-6 Alkyl, -C(=O)R 5a 、-NR 5b1 R 5b2 、-C(=O)OR 5c 、-C(=O)NR 5d1 R 5d2 , C 6-20 Aryl, one or more R 5-1-1 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 5-1-2 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 3-12 Cycloalkyl, with one or more R 5-1-3 Substituted C 3-12 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 5-1-4 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 5-1-5 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 5-1-6 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms, which are independently selected from O, S and N"; when there are multiple substituents, they may be the same or different; R 5-1-1 , R 5-1-2 , R 5-1-3 , R 5-1-4 , R 5-1-5 and R 5-1-6 are independently halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 5a , R 5b1 , R 5b2 , R 5c , R 5d1 and R 5d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds: N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(iso Butyrylpiperazin-1-yl)-1H -Indazole-5-sulfonamide, N-(1-cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-1-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide.

2. The heteroaromatic ring sulfonamide structure compound as shown in Formula I as claimed in claim 1, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound, characterized in that: The structure of the heteroaromatic ring sulfonamide structure compound shown in Formula I is shown in Formula II: in, represents a single bond or a double bond; A1 is C, CH or N; A3 is C or N; A4 is N or CR 4 ; A5 is NR 5 or CR 5 ; for R a1 is cyano or C 1-6 alkyl; R 1 for R 11 , R 12 , R 13 , R 14 , R 15 and R 16 Independently for C 1-6 Alkyl, with one or more R 1-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl, with one or more R 1-2 Substituted C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 1-3 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, one or more R 1-4 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 1-5 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 1-6 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 1-7 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; R 1-1 , R 1-2 , R 1-3 , R 1-4 , R 1-5 , R 1-6 and R 1-7 For halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 1a 、-NR 1b1 R 1b2 、-C(=O)OR 1c 、-C(=O)NR 1d1 R 1d2 、-S(O)2NR 1e1 R 1e2 、-S(O)2R 1f , C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, or "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; when there are multiple substituents, they may be the same or different; R 1a , R 1b1 , R 1b2 , R 1c , R 1d1 , R 1d2 , R 1e1 , R 1e2 and R 1f are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; n is 0, 1, 2, 3, 4, 5 or 6; R 2 For halogen, hydroxyl, cyano, oxo, C 1-6 Alkyl, with one or more R 2-1 Substituted C 1-6 Alkyl, C 3-8 Cycloalkyl, with one or more R 2-2 Substituted C 3-8 Cycloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 2a 、-NR 2b1 R 2b2 、-C(=O)OR 2c or -C(=O)NR 2d1 R 2d2 ; or, when n is 2, 3, 4, 5 or 6, any two R 2 connected to each other, independently together with the atoms in the ring to which they are connected, form a 3-8 membered carbocyclic ring or a 3-8 membered heterocyclic ring containing 1-3 heteroatoms independently selected from O, S and N; R 2-1 and R 2-2 are independently halogen, cyano, C 1-6 Alkyl-O-, hydroxyl, -C(=O)R 22a 、-NR 22b1 R 22b2 、-C(=O)OR 22c or -C(=O)NR 22d1 R 22d2 ; R 2a , R 2b1 , R 2b2 , R 2c , R 2d1 , R 2d2 , R 22a , R 22b1 , R 22b2 , R 22c , R 22d1 and R 22d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 3 is a 5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N, or is replaced by one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms, which are independently selected from O, S and N"; R 3-1 For halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C substituted by one or more halogens 1-6 Alkyl, with one or more -OC 1-6 Alkyl substituted C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC substituted by one or more halogens 1-6 Alkyl, pentafluorinated sulfur, or -SC substituted by one or more halogens 1-6 Alkyl; when there are multiple substituents, they may be the same or different; R 4 For hydrogen, halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 5 For hydrogen, C 1-6 Alkyl, or one or more R 5-1 Substituted C 1-6 alkyl; R 5-1 For deuterium, halogen, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, Hydroxyl, -OC 1-6 Alkyl, -C(=O)R 5a 、-NR 5b1 R 5b2 、-C(=O)OR 5c 、-C(=O)NR 5d1 R 5d2 , C 6-20 Aryl, one or more R 5-1-1 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 5-1-2 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 3-12 Cycloalkyl, with one or more R 5-1-3 Substituted C 3-12 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 5-1-4 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 5-1-5 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 5-1-6 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms, which are independently selected from O, S and N"; when there are multiple substituents, they may be the same or different; R 5-1-1 , R 5-1-2 , R 5-1-3 , R 5-1-4 , R 5-1-5 and R 5-1-6 are independently halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 5a , R 5b1 , R 5b2 , R 5c , R 5d1 and R 5d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds: N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide, N-(1-cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-1-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide.

3. The heteroaromatic ring sulfonamide structure compound as shown in Formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound as claimed in claim 1, characterized in that: In the structure shown in Formula I, A3 is C; A4 is N; A5 is NR 5 ; for R a1 is cyano or C 1-6 alkyl; Ring Y is "a 4-12-membered heterocycloalkyl group containing 1-3 heteroatoms independently selected from O, S and N" or "a 4-8-membered heterocycloalkenyl group containing 1-3 heteroatoms independently selected from O, S and N"; R 1 for R 11 and R 14 Independently for C 1-6 alkyl; n is 0, 1 or 2; R 2 For cyano, C 3-8 Cycloalkyl or C 1-6 alkyl; R 3 For one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms, which are independently selected from O, S and N"; R 3-1 is C substituted by one or more halogens 1-6 alkyl; R 5 C 1-6 alkyl; The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds: N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide, N-(1-cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-1-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide.

4. The heteroaromatic ring sulfonamide structure compound as shown in Formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound as claimed in claim 1, characterized in that: The heteroaromatic ring sulfonamide structure compound as shown in Formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound, which is Scheme 1, Scheme 2 or Scheme 3: Scheme 1: In the heteroaromatic sulfonamide structure compound shown in Formula I, represents a single bond or a double bond; A3 is C or N; A4 is N or CR 4 ; A5 is NR 5 or CR 5 ; for R a1 is cyano or C 1-6 alkyl; Ring Y is "a 4-12-membered heterocycloalkyl group containing 1-3 heteroatoms independently selected from O, S and N" or "a 4-8-membered heterocycloalkenyl group containing 1-3 heteroatoms independently selected from O, S and N"; R 1 for R 11 , R 12 , R 13 , R 14 , R 15 and R 16 Independently for C 1-6 Alkyl, with one or more R 1-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl, with one or more R 1-2 Substituted C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 1-3 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, one or more R 1-4 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 1-5 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 1-6 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 1-7 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; R 1-1 , R 1-2 , R 1-3 , R 1-4 , R 1-5 , R 1-6 and R 1-7 For halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 1a 、-NR 1b1 R 1b2 、-C(=O)OR 1c 、-C(=O)NR 1d1 R 1d2 、-S(O)2NR 1e1 R 1e2 、-S(O)2R 1f , C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, or "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; when there are multiple substituents, they may be the same or different; R 1a , R 1b1 , R 1b2 , R 1c , R 1d1 , R 1d2 , R 1e1 , R 1e2 and R 1f are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; n is 0, 1, 2, 3, 4, 5 or 6; R 2 For halogen, hydroxyl, cyano, oxo, C 1-6 Alkyl, with one or more R 2-1 Substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 2a 、-NR 2b1 R 2b2 、-C(=O)OR 2c or -C(=O)NR 2d1 R 2d2 ; or, when n is 2, 3, 4, 5 or 6, any two R 2 connected to each other, independently together with the atoms in the ring to which they are connected, form a 3-8 membered carbocyclic ring, or a 3-8 membered heterocyclic ring containing 1-3 heteroatoms, which are independently selected from O, S and N; R 2-1 For halogen, cyano, C 1-6 Alkyl-O-, hydroxyl, -C(=O)R 22a 、-NR 22b1 R 22b2 、-C(=O)OR 22c or -C(=O)NR 22d1 R 22d2 ; R 2a , R 2b1 , R 2b2 , R 2c , R 2d1 , R 2d2 , R 22a , R 22b1 , R 22b2 , R 22c , R 22d1 and R 22d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 3 is a 5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N, or is replaced by one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms, which are independently selected from O, S and N"; R 3-1 For halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C substituted by one or more halogens 1-6 Alkyl, with one or more -OC 1-6 Alkyl substituted C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC substituted by one or more halogens 1-6 Alkyl, pentafluorinated sulfur, or -SC substituted by one or more halogens 1-6 Alkyl; when there are multiple substituents, they may be the same or different; R 4 For hydrogen, halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 5 For hydrogen, C 1-6 Alkyl, or one or more R 5-1 Substituted C 1-6 alkyl; R 5-1 For deuterium, halogen, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, Hydroxyl, -OC 1-6 Alkyl, -C(=O)R 5a 、-NR 5b1 R 5b2 、-C(=O)OR 5c 、-C(=O)NR 5d1 R 5d2 , C 6-20 Aryl, one or more R 5-1-1 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 5-1-2 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 3-12 Cycloalkyl, with one or more R 5-1-3 Substituted C 3-12 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 5-1-4 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 5-1-5 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 5-1-6 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms, which are independently selected from O, S and N"; when there are multiple substituents, they may be the same or different; R 5-1-1 , R 5-1-2 , R 5-1-3 , R 5-1-4 , R 5-1-5 and R 5-1-6 are independently halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 5a , R 5b1 , R 5b2 , R 5c , R 5d1 and R 5d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds: N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide, N-(1-cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-1-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide; Scheme 2: The structure of the heteroaromatic ring sulfonamide structure compound shown in Formula I is shown in Formula II: in, represents a single bond or a double bond; A1 is C, CH or N; A3 is C or N; A4 is N or CR 4 ; A5 is NR 5 or CR 5 ; for R a1 is cyano or C 1-6 alkyl; R 1 for R 11 , R 12 , R 13 , R 14 , R 15 and R 16 Independently for C 1-6 Alkyl, with one or more R 1-1 Substituted C 1-6 Alkyl, C 3-10 Cycloalkyl, with one or more R 1-2 Substituted C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 1-3 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, one or more R 1-4 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 1-5 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 1-6 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 1-7 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; R 1-1 , R 1-2 , R 1-3 , R 1-4 , R 1-5 , R 1-6 and R 1-7 For halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 1a 、-NR 1b1 R 1b2 、-C(=O)OR 1c 、-C(=O)NR 1d1 R 1d2 、-S(O)2NR 1e1 R 1e2 、-S(O)2R 1f , C 3-10 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, or "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N"; when there are multiple substituents, they may be the same or different; R 1a , R 1b1 , R 1b2 , R 1c , R 1d1 , R 1d2 , R 1e1 , R 1e2 and R 1f are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; n is 0, 1, 2, 3, 4, 5 or 6; R 2 For halogen, hydroxyl, cyano, oxo, C 1-6 Alkyl, with one or more R 2-1 Substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C(=O)R 2a 、-NR 2b1 R 2b2 、-C(=O)OR 2c or -C(=O)NR 2d1 R 2d2 ; or, when n is 2, 3, 4, 5 or 6, any two R 2 connected to each other, independently together with the atoms in the ring to which they are connected, form a 3-8 membered carbocyclic ring or a 3-8 membered heterocyclic ring containing 1-3 heteroatoms independently selected from O, S and N; R 2-1 For halogen, cyano, C 1-6 Alkyl-O-, hydroxyl, -C(=O)R 22a 、-NR 22b1 R 22b2 、-C(=O)OR 22c or -C(=O)NR 22d1 R 22d2 ; R 2a , R 2b1 , R 2b2 , R 2c , R 2d1 , R 2d2 , R 22a , R 22b1 , R 22b2 , R 22c , R 22d1 and R 22d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 3 is a 5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N, or is replaced by one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms, which are independently selected from O, S and N"; R 3-1 For halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C substituted by one or more halogens 1-6 Alkyl, with one or more -OC 1-6 Alkyl substituted C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC substituted by one or more halogens 1-6 Alkyl, pentafluorinated sulfur, or -SC substituted by one or more halogens 1-6 Alkyl; when there are multiple substituents, they may be the same or different; R 4 For hydrogen, halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 5 For hydrogen, C 1-6 Alkyl, or one or more R 5-1 Substituted C 1-6 alkyl; R 5-1 For deuterium, halogen, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, Hydroxyl, -OC 1-6 Alkyl, -C(=O)R 5a 、-NR 5b1 R 5b2 、-C(=O)OR 5c 、-C(=O)NR 5d1 R 5d2 , C 6-20 Aryl, one or more R 5-1-1 Substituted C 6-20 Aryl, "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", 5-1-2 Substituted "5-12 membered heteroaryl containing 1-4 heteroatoms independently selected from O, S and N", C 3-12 Cycloalkyl, with one or more R 5-1-3 Substituted C 3-12 Cycloalkyl, "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", 5-1-4 Substituted "4-12 membered heterocycloalkyl containing 1-3 heteroatoms independently selected from O, S and N", C 4-8 Cycloalkenyl, with one or more R 5-1-5 Substituted C 4-8 Cycloalkenyl, "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms independently selected from O, S and N", or one or more R 5-1-6 Substituted "4-8 membered heterocycloalkenyl containing 1-3 heteroatoms, which are independently selected from O, S and N"; when there are multiple substituents, they may be the same or different; R 5-1-1 , R 5-1-2 , R 5-1-3 , R 5-1-4 , R 5-1-5 and R 5-1-6 are independently halogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; R 5a , R 5b1 , R 5b2 , R 5c , R 5d1 and R 5d2 are independently hydrogen, C 1-6 Alkyl, or C substituted by one or more halogen 1-6 alkyl; The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds: N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide, N-(1-cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-1-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide; Scheme 3: In the structure shown in Formula I, A3 is C; A4 is N; A5 is NR 5 ; for R a1 is cyano or C 1-6 alkyl; Ring Y is "a 4-12-membered heterocycloalkyl group containing 1-3 heteroatoms independently selected from O, S and N" or "a 4-8-membered heterocycloalkenyl group containing 1-3 heteroatoms independently selected from O, S and N"; R 1 for R 11 and R 14 Independently for C 1-6 alkyl; n is 0, 1 or 2; R 2 is cyano or C 1-6 alkyl; R 3 For one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms, which are independently selected from O, S and N"; R 3-1 is C substituted by one or more halogens 1-6 alkyl; R 5 C 1-6 alkyl; The heteroaromatic ring sulfonamide structure compound shown in Formula I is not one of the following compounds: N-(1-methylcyclopropyl)-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1-ethyl-6-fluoro-7-(4-(isobutyrylpiperazin-1-yl)-1H-indazole-5-sulfonamide, N-(1-Cyanocyclopropyl)-6-fluoro-7-(4-(isopropylsulfonyl)piperazin-1-yl)-methyl-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazole-5-sulfonamide.

5. The heteroaromatic ring sulfonamide structure compound as shown in formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound as claimed in claim 1 or 2, characterized in that: The structure of the heteroaromatic ring sulfonamide structure compound shown in Formula I or II is shown in Formula III, R a1 is cyano or C 1-6 alkyl; R 1 for R 11 and R 14 Independently for C 1-6 alkyl; n is 0 or 1; R 2 C 1-6 alkyl; R 3 For one or more R 3-1 Substituted "5-6 membered heteroaryl containing 1-4 heteroatoms, which are independently selected from O, S and N"; R 3-1 is C substituted by one or more halogens 1-6 alkyl; R 5 C 1-6 alkyl.

6. The heteroaromatic ring sulfonamide structure compound as shown in Formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound as claimed in claim 1, characterized in that: When R 3 is a 5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N, or is replaced by one or more R 3-1 When the substituted "5-6 membered heteroaryl group containing 1-4 heteroatoms independently selected from O, S and N" is present, the R 3 "a 5-6 membered heteroaryl group containing 1-3 heteroatoms, wherein the heteroatoms are independently selected from S and N"; and / or, when R 3-1 is C substituted by one or more halogens 1-6 When alkyl, the R 3-1 C is substituted with two or three halogens 1-2 alkyl; and / or, when ring Y is "a 4-12-membered heterocycloalkyl group containing 1-3 heteroatoms independently selected from O, S and N", said ring Y is "a 4-8-membered heterocycloalkyl group containing 1-2 heteroatoms independently selected from O, S and N"; and / or, when ring Y is "a 4-8 membered heterocycloalkenyl group containing 1-3 heteroatoms independently selected from O, S and N", said ring Y is "a 4-6 membered heterocycloalkenyl group containing 1-3 heteroatoms independently selected from O, S and N"; and / or, A3 is C; and / or, A4 is N; and / or, A5 is NR 5 ; and / or, R a1 is cyano or C 1-6 alkyl; and / or, n is 0, 1 or 2; and / or, R 2 For cyano, C 3-8 Cycloalkyl or C 1-6 alkyl; and / or, when R a1 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 1-1 , R 1-2 , R 1-3 , R 1-4 , R 1-5 , R 1-6 , R 1-7 , R 1a , R 1b1 , R 1b2 , R 1c , R 1d1 , R 1d2 , R 1e1 , R 1e2 , R 1f , R 2 , R 2-1 , R 2-2 , R 2a , R 2b1 , R 2b2 , R 2c , R 2d1 , R 2d2 , R 22a , R 22b1 , R 22b2 , R 22c , R 22d1 , R 22d2 , R 3-1 , R 4 , R 5 , R 5-1 , R 5-1-1 , R 5-1-2 , R 5-1-3 , R 5-1-4 , R 5-1-5 , R 5-1-6 , R 5a , R 5b1 , R 5b2 , R 5c , R 5d1 and R 5d2 The definition of C 1-6 When the C 1-6 Alkyl is C 1-4 alkyl.

7. The heteroaromatic ring sulfonamide structure compound as shown in Formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound as claimed in claim 1, characterized in that: for and / or, R a1 is cyano or methyl; and / or, R 1 for and / or, R 2 is cyano, cyclopropyl, ethyl, n-propyl or methyl; and / or, R 3 for and / or, R 5 is methyl; and / or, ring Y is 8. The heteroaromatic ring sulfonamide structure compound as shown in Formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound as claimed in claim 1, characterized in that: for 9. The heteroaromatic ring sulfonamide structure compound as shown in Formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotope compound as claimed in claim 1, characterized in that: The compound shown in formula I is any of the following structures:

10. A pharmaceutical composition comprising substance A and pharmaceutical excipients; the substance A is a therapeutically effective amount of a heteroaromatic ring sulfonamide structure compound as shown in formula I as described in any one of claims 1 to 9, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or an isotope compound thereof.

11. Use of a substance A in the preparation of a PARG inhibitor, wherein the substance A is a heteroaromatic ring sulfonamide structure compound as shown in formula I as described in any one of claims 1 to 9, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or an isotope compound thereof.

12. Use of a substance A in the preparation of a drug, wherein the drug is used to treat or prevent PARG-mediated diseases; the substance A is a heteroaromatic ring sulfonamide structure compound as shown in formula I as described in any one of claims 1 to 9, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or an isotope compound thereof.

13. Use of a substance A in preparing a drug, wherein the drug is used to treat or prevent cancer; the substance A is a heteroaromatic sulfonamide structure compound as shown in formula I as described in any one of claims 1 to 9, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or an isotope compound thereof; the cancer is one or more of colon cancer, appendix cancer, pancreatic cancer, MYH-related polyposis, blood cancer, breast cancer, endometrial cancer, gallbladder cancer, bile duct cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head or neck cancer, bone cancer, skin cancer, rectal cancer, liver cancer, esophageal cancer, gastric cancer, thyroid cancer, bladder cancer, lymphoma, leukemia and melanoma.

Images